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5Preface
It is our great pleasure to present the European Drug Report (EDR) 2019: Trends and 
Developments, the EMCDDA’s flagship publication. This report provides an analysis of the 
latest data on the drug situation and responses to it across the European Union, Norway 
and Turkey. It is supported by other, online information resources, including our Statistical 
Bulletin, containing source data. The EDR package also includes 30 Country Drug Reports, 
which provide an overview of the current situation for all countries participating in the EU 
drug information network.
Interlinked elements allowing access to available data and analysis on the drugs problem 
in Europe and at national level
 
 
EUROPEAN DRUG REPORT PACKAGE 2019
Trends and Developments
providing a top-level analysis
of key developments
(print and PDF)
Statistical Bulletin
containing full data arrays 
and methodological
information (online)
EU 28, Turkey 
and Norway
Country Drug Reports
graphic-rich reports presenting 
summaries of national drug 
phenomena (online)
2019
Country Drug Reports 2019
The EMCDDA’s aim is to contribute to a healthier and more secure Europe. We seek to do 
this by providing the best available evidence to support the development of informed and 
targeted drug policies and actions. Our flagship report gives stakeholders a timely overview 
of the drug situation, which is necessary for developing effective responses to today’s 
problems. Moreover, it affords an analysis of new threats, allowing us to prepare for future 
challenges arising in this fast-changing and complex area.
This year’s report arrives at a critical time for reflection on drug policy developments, 
especially given the international debate on the appropriate follow-up to the United 
Nations special session on the world drug problem in 2016. Next year will see the final 
evaluation of the current EU drugs strategy (2013-20). During this period, Europe has 
witnessed some dramatic changes in the challenges the drugs area presents, including 
the appearance of more non-controlled substances. We have also seen significant 
changes in the drug market and drug use; and our understanding of what constitutes 
effective interventions has increased. A market dominated by plant-based substances 
imported into Europe has evolved into one where synthetic drugs and production within 
Europe have grown in importance. Globalisation and technological advances have 
reshaped the strategic issues that European policymakers need to consider. We are proud 
of the EMCDDA’s international reputation for keeping pace with these changes and 
providing the information necessary to help support the cooperation and coordination that 
the EU drug strategy envisages.
European Drug Report 2019: Trends and Developments
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The European Union and its Member States are committed to achieving the goals adopted 
in the United Nations 2030 Agenda for Sustainable Development. Many aspects of these 
goals relate directly and indirectly to drug problems. For example, the production and 
trafficking of drugs can cause great harm to the physical environment, institutional 
structures and the quality of life attainable for citizens in the countries affected. Goals 3.3 
and 3.5 focus on ending the epidemics of infectious diseases and enhancing the 
prevention and treatment of drug use problems. Within this context, Europe is committed 
to pursuing the goal of eliminating viral hepatitis among people who inject drugs over the 
next decade. The hepatitis C virus is highly prevalent among this population, but recent 
advances in the medications available for treating the infection have made the possibility 
of eliminating the virus an attainable goal. This is why, in this year’s European Drug Report, 
we give special emphasis to the need to scale up the provision of prevention, testing and 
treatment as a critical objective to achieving this important public health goal.
Finally, we must express our gratitude to our national counterparts in the Reitox network of 
national focal points, our other national and international partners and the Scientific 
Committee of the EMCDDA, without whose support this report would not be possible. We 
are also grateful to our partners at European level, in particular the European Commission, 
Europol, the European Centre for Disease Prevention and Control and the European 
Medicines Agency. Additionally, we are thankful to the specialised networks that have 
collaborated with us, enriching our report with leading-edge and innovative data.
Laura d’Arrigo
Chair, EMCDDA Management Board
Alexis Goosdeel
Director, EMCDDA


9Introductory note and acknowledgements
This report is based on information provided to the EMCDDA by the EU Member States, the candidate country Turkey 
and Norway in an annual reporting process.
The purpose of the current report is to provide an overview and summary of the European drug situation and 
responses to it. The statistical data reported here relate to 2017 (or the last year available). Analysis of trends is based 
only on those countries providing sufficient data to describe changes over the period specified. The reader should also 
be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically 
and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in 
this report. Although considerable improvements can be noted, both nationally and in respect to what is possible to 
achieve in a European level analysis, the methodological difficulties in this area must be acknowledged. Caution is 
therefore required in interpretation, in particular when countries are compared on any single measure. Caveats and 
qualifications relating to the data are to be found in the online version of this report and in the Statistical Bulletin, 
where detailed information on methodology, qualifications on analysis and comments on the limitations in the 
information set available can be found. Information is also available there on the methods and data used for European 
level estimates, where interpolation may be used.
The reference period for all graphics, analysis and data included in this report is the drug situation up to the end of 
2018. All grouping, aggregates and labels therefore reflect the situation as it was in 2018 in respect to the composition 
of the European Union and the countries participating in EMCDDA reporting exercises. Due to the time needed to 
compile and submit data many of the annual data sets included here are from the reference year January to December 
2017.
The EMCDDA would like to thank the following for their help in producing this report:
the heads of the Reitox national focal points and their staff;
the services and experts within each Member State that collected the raw data for this report;
the members of the Management Board and the Scientific Committee of the EMCDDA;
the European Parliament, the Council of the European Union — in particular its Horizontal Working Party on Drugs 
— and the European Commission;
the European Centre for Disease Prevention and Control (ECDC), the European Medicines Agency (EMA) and 
Europol;
the Pompidou Group of the Council of Europe, the United Nations Office on Drugs and Crime, the WHO Regional 
Office for Europe, Interpol, the World Customs Organisation, the European School Survey Project on Alcohol and 
Other Drugs (ESPAD), the Sewage Analysis Core Group Europe (SCORE), the European Drug Emergencies Network 
(Euro-DEN Plus), the European Syringe Collection and Analysis Project Enterprise (ESCAPE) network, the Trans-
European Drug Information network (TEDI) and the European Web Survey on Drugs group;
the Translation Centre for the Bodies of the European Union and the Publications Office of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national 
focal points in the EU Member States, the candidate country Turkey, Norway and at the European Commission. 
Under the responsibility of their governments, the focal points are the national authorities providing drug 
information to the EMCDDA. The contact details of the national focal points may be found on the EMCDDA 
website.
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Understanding Europe’s 
drug situation in 2019
The EMCDDA’s latest analysis of the 
European drug phenomenon reveals 
a market that is both resilient and 
reflective of developments taking place 
at the global level. The continuing 
health and security problems presented 
by established and newer illicit drugs 
create a challenging policy context for 
the shaping and implementation of 
effective responses. The 2019 
European Drug Report provides 
a snapshot of the drug situation in 
Europe based on the latest data 
available. This introductory section 
provides a brief analytical commentary 
on some of the important issues that 
are currently featuring on Europe’s drug 
policy agenda.
Opioids: efforts still needed to address an evolving 
problem
The European drug problem was once defined by injecting 
heroin use. Today, new heroin treatment demands are low 
by historical standards, rates of injecting use have fallen, 
and the number of new cases of HIV attributed to drug 
injecting each year has decreased by around 40 % over the 
last decade. This is good news. European countries can be 
applauded for introducing the pragmatic harm reduction 
and treatment measures that contributed to these 
successes. In contrast, elsewhere, opioid problems have 
continued to grow, resulting in escalating public health 
costs in both North America and some of the countries 
bordering the European Union. However, despite the 
improvements seen in Europe, the use of opioids 
continues to make a major contribution to the health and 
social costs attributable to drug use in Europe, and the 
threats posed by this class of drug may even be growing.
An analysis of the responses available for opioid-related 
problems shows that, in a number of countries, especially 
in the eastern parts of Europe, the provision of effective 
harm reduction and treatment remains inadequate. There 
are also signs that in some countries with historically good 
service coverage, the situation has deteriorated. At the 
same time, the needs of an ageing and often increasingly 
vulnerable cohort of long-term opioid users continue to 
grow. Overdose deaths reflect this, with victims now on 
average aged 39 years, as does the high prevalence of 
both physical and psychological health problems among 
this group. Moreover, an overall increase in drug-related 
deaths has been observed over the last 5 years, with 
increases reported in all age groups above the age of 
30 years. Supply side indicators show signs that the threat 
may be growing. The quantity of heroin seized has 
increased, and the purity of the drug remains relatively 
high and the price relatively low, suggesting high 
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availability in many parts of Europe. Heroin-processing 
laboratories have also recently been detected in some EU 
countries, which represents a worrying development.
Combatting viral hepatitis
Europe is committed to the international 2030 Agenda for 
Sustainable Development. This global policy framework 
includes combatting viral hepatitis. Within the European 
Union, this is of particular relevance for people who inject 
drugs, as these are not only the people with the highest 
burden of the disease, but also the ones at highest risk of 
transmission. Addressing the health impact of viral 
hepatitis by 2030 will therefore depend on scaling up 
prevention measures and access to testing and treatment 
for hepatitis B and C for this group.
Hepatitis strategies are now in place in 17 EU countries 
and Norway, and an increasing number of countries are 
providing unrestricted access to better tolerated and more 
effective, direct-acting antiviral medications. Nonetheless, 
more needs to be done. HCV screening is a critical entry 
point to effective hepatitis care and helps prevent further 
transmission. Community-based drugs services can play 
an important role here. In many countries, however, 
effective testing policies and appropriate referral pathways 
are not in place. Professional resistance can also exist to 
treating drug users, and the benefits that this investment 
in care delivers, both to individuals and to the wider 
community, is not always recognised. The EMCDDA is 
developing tools to support the implementation of viral 
hepatitis treatment in drug treatment settings. These 
include a checklist to identify barriers to the uptake of HCV 
testing and treatment, a knowledge questionnaire for 
service staff, and illustrative case studies demonstrating 
how innovative community-based testing approaches can 
make a valuable contribution to the response to this 
disease.
Synthetic opioids now play a bigger role
In the United States and Canada, the current opioid 
epidemic is being driven by the use of synthetic opioids, 
particularly fentanyl derivatives. This is not the case in 
Europe, but concerns do exist in this area. Around 50 new 
synthetic opioids have been reported to the EU Early 
Warning System on new psychoactive substances. Many 
of these substances have been linked to severe poisonings 
and deaths. Some, like carfentanil, are extremely potent, 
meaning that they can be trafficked in very small 
quantities, which are difficult to detect but can equate to 
many thousands of user doses. In addition, synthetic 
opioids that are usually used as medicines appear to be 
playing an increasing role in the drug problem in many 
parts of Europe — these include drugs used for 
substitution treatment and pain relief. One in every five of 
those entering drug treatment for an opioid-related 
problem now reports a synthetic opioid, rather than heroin, 
as their main problem drug; and these drugs are becoming 
more commonly detected in drug overdose cases. Despite 
this threat, the current capacity to detect and report on the 
availability, use and consequences of synthetic opioids 
remains limited. Improving the sensitivity of information 
resources in this area must therefore be regarded as 
a priority.
The value of toxicological and forensic data 
sources
Drug overdose deaths are rarely associated with the 
consumption of one substance alone. Modern drug 
consumption patterns are highly dynamic, with an 
increased number of drugs appearing on the market, and 
consumers typically — knowingly or unknowingly — using 
a number of different substances. This means that without 
good forensic and toxicological data, new health threats 
may be overlooked. There is a risk therefore that the role of 
potent new psychoactive substances, like fentanyl 
derivatives, in overdose deaths may be missed, especially 
when they are consumed alongside more established 
drugs like heroin. Some EU Member States, particularly in 
northern Europe, have invested in improving the availability 
and sensitivity of toxicological data and this now allows 
a better understanding of drug trends and health threats. 
Introducing comprehensive screening and increasing the 
sensitivity of testing in Sweden, for example, resulted in 
a doubling of the number of fentanyl cases detected 
among the samples of drug-related deaths examined. 
A recent EMCDDA study shows, however, that not all 
laboratories have the capacity to detect the more 
uncommon substances. For forensic and toxicological 
investigation, the availability of reference standards is 
essential; for new psychoactive substances, however, 
these are often not available in many laboratories. In 
addition, the absence of European forensic toxicology 
guidelines for drug-related death investigations is a barrier 
to improving monitoring and practice in this area. More 
 Europe is committed  
 to the international 2030  
 Agenda for Sustainable  
 Development 
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generally, as synthetic drugs of all types are likely to 
continue to grow in importance, greater investment in 
toxicological and forensic data sources will be needed.
Innovative monitoring tools provide insight on 
emerging trends
This year’s European Drug Report draws on a selection of 
newer targeted data sources. These ‘leading edge’ 
indicators are not representative of the general population 
and have other limitations; however, they do provide 
useful, timely and complementary data that offer valuable 
insights into drug use in Europe (see Figure 1). For 
example, wastewater analysis now provides a snapshot of 
drug volumes consumed at community level in cities 
across Europe. One of the benefits of this data source is 
that the information can be reported rapidly, and can 
thereby provide a potential early warning of changes in 
drug consumption. This is illustrated by new data for 2018, 
recently released by the SCORE group and the EMCDDA, 
which point to greater geographical diffusion and an 
overall increase in the consumption of all the commonly 
used classes of stimulant drugs.
Other new data sources included in this year’s report 
include the European Web Survey on Drugs. Based on 
a sample of drug users recruited online, the results of this 
survey provide information about patterns of use and 
purchases of commonly used illicit drugs. Information from 
drug checking services, which enable people to have their 
drugs analysed and to receive information on their content, 
is also reviewed here to provide insights into drug use in 
specific recreational settings.
Hospital emergency data on acute drug-related harms can 
increase our understanding of the public health impact of 
the use of the drugs in Europe. Drug-related acute toxicity 
presentations in selected hospitals in 18 European 
countries are monitored by the European Drug 
Emergencies Network (Euro-DEN Plus). The findings from 
this year’s analysis illustrate how the drugs responsible for 
emergency presentations can vary across Europe. 
Stimulants were associated, for example, with a large 
number of emergencies, but presentations involving 
amphetamines were most common in the north and east 
of Europe, whereas cocaine was the predominant 
stimulant in southern and western countries.
The role that stimulants can play in injecting drug use is 
also demonstrated by a new pilot study that analysed the 
drug residues extracted from used syringes collected at 
needle exchange sites in five European cities. In all but one 
site, stimulants were the most common substance 
detected. Half of the syringes analysed contained traces of 
two or more drugs, the most frequent combination being 
a mix of stimulant and opioid. These new sources of 
information offer the chance to corroborate and 
complement existing data sources, improving our 
awareness of the less well-observed forms of drug use.
New indicators to complement existing data sources
NEW 
INDICATORS
Hospital 
emergencies
Drug 
checking services
Web surveys
Wastewater 
analysis
Syringe residue 
analysis
FIGURE 1
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Europe’s cocaine market continues to grow
Current data on cocaine show that both the number of 
seizures and the volumes seized are at an all-time high. 
Cocaine enters Europe through numerous routes and 
means, but the growth in large-volume trafficking, through 
major ports, using containers, stands out. Increased 
availability of the drug is also suggested by the highest 
estimates of cocaine purity at retail level in a decade. 
A reorganisation of the cocaine supply chain and the 
players involved is visible at the middle and retail level, 
with the emergence of fragmented, looser and more 
horizontal organisational structures. Smaller groups have 
been able to enter the market by using a range of 
information technology like encryption, darknet market 
places, social media for dealing and cryptocurrencies. 
Entrepreneurship in the competitive cocaine market is 
evident from innovative distribution strategies, such as 
cocaine-exclusive call-centres. These new methods appear 
to reflect to some extent the type of disruption seen in 
other areas facilitated by the common use of smartphones 
— a potential ‘Uberisation’ of the cocaine trade — 
a competitive market in which sellers compete by offering 
additional services such as fast and flexible delivery 
options.
Cocaine: health harms more evident
Estimating the prevalence of problematic cocaine use is 
particularly difficult, as this drug is less visible in 
established indicators, which tend to be more focused on 
opioid-related problems. Nonetheless, there are signs that 
increased cocaine availability is resulting in growing health 
costs. Since 2014, the number of new clients entering 
treatment for cocaine problems, although still relatively 
low, has increased by over 35 %, with around two-thirds of 
countries noting an increase. In some countries, cocaine 
has been associated with recent increases in drug-related 
deaths. The drug is often detected alongside opioids in 
overdose deaths in those parts of Europe where it is the 
predominant stimulant. In addition, the role played by 
cocaine in deaths linked to cardiovascular disease may go 
unreported. Where data are available, they show an overall 
increase in cocaine-related emergency presentations, with 
cocaine being the most commonly reported illicit 
substance in the 18-country Euro-DEN study. Cocaine was 
also found in a quarter or more of the syringes tested in 
three of the five cities participating in a pilot exercise of the 
utility of syringe residue analysis for mapping patterns of 
injecting drug use. The new data available also suggest 
that the use of crack cocaine, a smokable form of the drug, 
which is particularly associated with problematic use, may 
be spreading. Increases in the number of crack cocaine 
clients entering treatment since 2014 have been reported 
in Belgium, Ireland, France, Italy, Portugal, as well as in the 
United Kingdom, the European country that has been most 
associated with crack use.
The evidence available to support what constitutes 
effective services for cocaine users remains relatively 
weak, and targeted programmes for cocaine users are 
currently limited in Europe. This is beginning to change, 
with some countries now introducing more specialised 
harm reduction interventions. Overall, however, as needs in 
this area appear to be growing, investment is urgently 
needed in the development and evaluation of interventions 
of all types, but especially effective treatment models, if 
services are to be better placed to successfully engage 
with this client group.
Europe’s international role in synthetic drug 
production
Synthetic drug production in Europe, although difficult to 
monitor, appears to be growing, diversifying and becoming 
more innovative. This expansion can be seen from recent 
data documenting increased seizures of precursor 
chemicals. The EMCDDA-Europol European Drug Markets 
Report, to be published in late 2019, will provide an 
in-depth analysis of these developments. The detection of 
production laboratories, waste-dumping sites, and the 
potency and variety of synthetic drugs available on the 
European market are key concerns in this area.
There are now also growing indications of Europe’s 
importance in the global market for synthetic drugs. These 
signals include significant seizures of various substances 
at EU borders; the fact that more MDMA is now seized in 
Turkey than in the European Union as whole; and the 
detection of facilities in Europe producing 
methamphetamine and other synthetic drugs intended for 
export. The infrastructure that permits goods to rapidly 
move between countries has increasingly been used to 
facilitate trafficking of controlled drugs, new psychoactive 
substances, precursors and other chemicals essential for 
drug production into the European Union. The same 
 Estimating the prevalence  
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infrastructure is also sometimes used to traffic synthetic 
drugs — particularly MDMA, but also other substances 
— to non-EU countries.
Synthetic drug production also appears to be driving the 
spread of methamphetamine use to new countries within 
the European Union. Globally, methamphetamine 
represents the greatest challenge in the synthetic drug 
area. In Europe, methamphetamine use has been 
concentrated in a few countries with long-standing 
problems. This is still largely the case today, but despite 
the widespread availability of other stimulants, analysis of 
wastewater residues suggest the drug is beginning to 
diffuse to new countries. Laboratory detections also point 
to some scaling-up of production and production for 
non-EU markets.
Cannabis: new developments for Europe’s most 
established drug
Cannabis is one of the longest-established drugs in 
Europe. It is the most commonly used illicit drug, with 
nearly 20 % of those in the 15-24 age group reporting 
having used cannabis in the last year. Internationally and 
within Europe, cannabis use continues to be a topic that is 
generating significant policy and public interest, as new 
developments are triggering debate on how society should 
respond to this substance.
A discussion is taking place about the therapeutic value of 
cannabis, cannabis preparations and medicines derived 
from the cannabis plant. Some countries have legalised 
cannabis, provoking a consideration of the costs and 
benefits of different regulatory and control options. This is 
a complex area. In Europe, considerable policing resources 
go into cannabis control, with over half of the 1.2 million 
use or possession for personal use offences reported in 
2017 related to cannabis. Involvement in the cannabis 
market can also be a driver for youth criminality and 
a major source of income for organised crime. In addition, 
our understanding of the potential health risks from 
cannabis use, especially among the young, has grown. 
Cannabis is now the substance most often named by new 
entrants to specialist drug treatment services as their main 
reason for seeking help. This is worrying, as over the last 
few years the EMCDDA’s overall assessment has been that 
cannabis trends have remained largely stable. Now, 
however, this is being challenged by new data, where 
a number of countries are reporting increased use among 
younger age cohorts.
Adding to this complexity, new forms of cannabis have 
been developed in recent years as a result of advances in 
cultivation, extraction and production techniques. Hybrid 
multi-strain plants yielding higher-potency cannabis have 
begun to replace established forms of the plant both 
within Europe and in Morocco, where much of the 
cannabis resin used in Europe originates. A recent 
EMCDDA-supported study shows that for both cannabis 
resin and herb the potency has increased over the last 
decade. The creation of legal recreational cannabis 
markets where the drug has been legalised is also driving 
innovation, with the development of new cannabis 
products such as edibles, e-liquids and concentrates. 
Some of these are now appearing on the European market, 
where they represent a new challenge for detection and 
drug control.
Recognising the now dynamic and complex nature of the 
cannabis policy sphere, the EMCDDA has launched a new 
series of publications that provide evidence reviews and 
analysis on this area. These include an overview of the 
development of medicinal cannabis provision in the 
European Union. Informed debate in this area is inhibited 
by the absence of a common conceptual understanding of 
medicinal cannabis. This is complicated by the diversity of 
products available, which can range from medicinal 
products containing compounds from the cannabis plant, 
to raw cannabis preparations.
Low-THC cannabis products raise regulatory 
issues
Another example of the rapid developments taking place 
concerning cannabis has been the appearance in the last 
2 years of low-strength herbal cannabis and cannabis oils 
for sale in health food shops or specialist shops in some 
EU countries. Sales take place based on the claim that 
these products have little or no intoxicating effect and 
therefore are not controlled under drug laws. Cannabis 
contains many different chemicals, but two cannabinoids, 
tetrahydrocannabinol (THC) and cannabidiol (CBD), attract 
the most attention. THC is the main substance found in 
cannabis responsible for its psychoactive effects. Products 
containing CBD are increasingly marketed with claims 
about their beneficial effects. The complex and evolving 
literature on the evidence for medicinal use of both THC 
and CBD has been addressed in a recent EMCDDA 
publication. The new products claim to have less than 
0.2 % or 0.3 % THC and broadly fit within two categories of 
products: one aimed at cannabis users for smoking and 
one — formulations like oils and creams — aimed people 
interested in possible healthcare uses. Some EU Member 
States regard low-THC products as cannabis extracts 
subject to criminal penalties; others consider them 
medicines that cannot be sold without authorisation; a few 
17
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classify them as products that do not pose a threat to 
public health and so do not require any licence for trade. 
This development is raising issues for regulation at both 
EU and national level.
Harnessing digitalisation for health benefit
Young people are an important target group for many drug 
interventions. They are likely to be the section of the 
population who are most familiar with and open to the use 
of information and communications technology in many 
areas of their life. They are also likely to be the group most 
willing to accept and benefit from the use of this 
technology for the delivery of drug prevention, treatment 
and harm reduction interventions. This year’s European 
Drug Report reviews some of the new developments in the 
mobile or m-health areas, which aim to address a wide 
range of issues, from access to services to providing skills 
training to those working in the drugs area. Developments 
in this field make use of online resources and mobile 
applications, with some recent innovative approaches 
exploring how virtual reality may, for example, be utilised in 
drug treatment, helping patients to develop resilience to 
drug cues or reduce craving. An important note of caution 
is merited here, as the new applications in this area are not 
always accompanied by robust quality standards, data 
protection rules and evaluation evidence. As in all other 
areas of healthcare, these will be essential elements, if the 
potential benefits promised by new technology for drug 
interventions are to be realised.
Strengthening the EU Early Warning System and 
risk assessment on new psychoactive substances
In 2018, new psychoactive substances were reported to 
the EU Early Warning System on new psychoactive 
substances at a rate of about one per week. At 55, the 
number of new drugs detected in 2018 is similar to the 
number found in 2017, but much reduced compared with 
2013 and 2014. While this may suggest a fall-off in 
innovation in this area, it should be noted that a significant 
number of substances that have already been notified 
continue to appear on the European drug market each 
year, suggesting that substances may persist in the market 
over time. There are also changes in the type of 
substances being observed, potentially signalling that new 
psychoactive substances are increasingly more targeted at 
the long-term and more problematic drug users. Whereas, 
for example, the EU Early Warning System on new 
psychoactive substances continues to receive reports of 
a diverse range of substances, more synthetic opioids and 
benzodiazepines are now appearing.
Early warning and risk assessment are central to Europe’s 
response to developments in the new psychoactive 
substances area. In 2018, the European system was 
revised to provide a strengthened and accelerated EU 
capacity to detect, assess and respond to health and 
social threats posed by new drugs. This not only provides 
for early warning across Europe, but also a possibility of 
faster risk assessment and control of substances at the 
European level. The changes also strengthen the network 
that supports the EMCDDA and Europol in this work, with 
formal working agreements now in place between the 
EMCDDA and the European Medicines Agency (EMA), the 
European Food Safety Authority (EFSA), the European 
Centre for Disease Prevention and Control (ECDC) and the 
European Chemicals Agency (ECHA).
 Young people are an important  
 target group for many drug  
 interventions 
1 In the global context,  
 Europe is an important  
 market for drugs 
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Drug supply and the market
In the global context, Europe is an 
important market for drugs, supplied 
from both domestic production and 
trafficking from other world regions. 
South America, West Asia and North 
Africa are important source areas for 
illicit drugs entering Europe, while China 
is an important source country for new 
psychoactive substances. In addition, 
some drugs and precursors are 
transited through Europe en route to 
other continents. Europe is also 
a producing region for cannabis and 
synthetic drugs; cannabis production is 
mostly for local consumption, while 
some synthetic drugs are manufactured 
for export to other parts of the world.
Monitoring drug markets, supply and laws
The analysis presented in this chapter draws on 
reported data on drug seizures, drug precursor 
seizures and stopped shipments, dismantled drug 
production facilities, drug laws, drug law offences, 
retail drug prices, purity and potency. In some cases, 
the absence of seizure data from key countries 
makes the analysis of trends difficult. A range of 
factors can influence trends, including user 
preferences, changes in production and trafficking, 
law enforcement activity levels and priorities and the 
effectiveness of interdiction measures. Full data sets 
and methodological notes can be found in the online 
Statistical Bulletin.
Also presented here are data on notifications and 
seizures of new psychoactive substances reported to 
the EU Early Warning System by the national 
partners of the EMCDDA and Europol. As this 
information is drawn from case reports rather than 
routine monitoring systems, seizure estimates 
represent a minimum. A full description of the Early 
Warning System on new psychoactive substances 
can be found on the EMCDDA website.
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Sizeable markets for cannabis, heroin and amphetamines 
have existed in many European countries since the 1970s 
and 1980s. Over time, other substances also established 
themselves — including MDMA and cocaine in the 1990s. 
The European drug market continues to evolve, with a wide 
range of new psychoactive substances emerging over the 
last decade. Recent changes in the illicit drug market, 
largely linked to globalisation and new technology, include 
innovation in drug production and trafficking methods, the 
establishment of new trafficking routes and the growth of 
online markets.
Illicit drug markets in Europe: 
complex and multi-level
Illicit drug markets encompass a complex set of interlinked 
activities, including production, trafficking, distribution and 
sale to the end consumer. They span large geographical 
distances. Different actors may be involved at the various 
stages, but organised criminal groups play a dominant role 
in the illicit drugs business, worth billions of euros each 
year.
At the retail level, the sale of drugs is still conducted 
primarily through direct contact between suppliers and 
consumers. Mobile technology and encryption, however, 
are increasingly being exploited by drug dealing networks. 
Online platforms for the sale of illicit drugs, while still 
a relatively minor component of the overall market, have 
been growing in importance in recent years. Online 
markets may be found on the surface web — the indexed 
or searchable part of the web — including web shops and 
social media platforms, or on the ‘darknet’ — an encrypted 
network, requiring special tools to access — where sellers 
and buyers can conceal their identities.
Over 100 global darknet markets have been in existence at 
various times since anonymous online markets emerged in 
2010. In July 2017, AlphaBay, the largest marketplace to 
have existed so far, was taken down in an international 
police operation, which also saw the end of another large 
site, Hansa market. This law enforcement operation may 
have eroded consumer confidence in the security of these 
marketplaces. Nevertheless, an EMCDDA and Europol 
analysis shows that revenues and trade volumes 
associated with drug sales across the darknet had 
returned to pre-enforcement levels one year later.
Over a million seizures of illicit drugs
Seizures of illicit drugs by law enforcement agencies are 
an important indicator of drug markets, with over 
1.1 million seizures of illicit drugs reported in 2017 in 
Europe. The majority of these reported seizures involve 
small quantities of drugs confiscated from users. However, 
a small number of multi-kilogram consignments of drugs 
account for most of the total quantity of drugs seized. The 
three countries that report the highest numbers of 
seizures, together accounting for over two-thirds of all drug 
seizures in the European Union are Spain, the United 
Kingdom and France. However, data on the number of 
seizures are not available for the Netherlands, while 2015 
data are the most recent available for Germany and 
Slovenia, adding a degree of uncertainty to the analysis. 
Cannabis is the most commonly seized drug, accounting 
for almost three-quarters of the total number of seizures in 
Europe (Figure 1.1).
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Cannabis: seizures and potency increase, price 
remains stable
Herbal cannabis (‘marijuana’) and cannabis resin 
(‘hashish’) are the two main cannabis products found on 
the European drugs market. Cannabis oil is comparatively 
rare, although some large bulk seizures have been reported 
in the last few years. Herbal cannabis consumed in Europe 
is mainly cultivated within Europe, though some is 
trafficked from external countries. The herbal cannabis 
produced in Europe is mostly cultivated indoors. Cannabis 
resin is mostly imported from Morocco, with Libya 
emerging as a major hub for resin trafficking. Reports are 
emerging of some resin production in the European Union, 
while the production of ‘nederhash’ has been documented 
for a number of years in the Netherlands. In addition, the 
Western Balkans is a source of both herbal cannabis and, 
more recently, cannabis oil.
In 2017, EU Member States reported 782 000 seizures of 
cannabis products, including 440 000 seizures of herbal 
cannabis, 311 000 of cannabis resin and 22 700 of 
cannabis plants. The number of seizures of herbal 
cannabis has exceeded that of cannabis resin since 2009. 
However, the quantity of cannabis resin seized is more 
than double that of herbal cannabis (466 versus 
209 tonnes). In part, this is a consequence of cannabis 
resin being trafficked in larger volumes across national 
borders, making interdiction more likely. Because of its 
proximity to Morocco, Spain is particularly important when 
it comes to quantities of cannabis resin seized, accounting 
for almost three-quarters (72 %) of the total quantity 
seized in the European Union in 2017 (Figure 1.2).
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The numbers of cannabis seizures reported in the 
European Union, both for resin and herbal products, have 
been relatively stable since 2012 (Figure 1.3). However, 
following a decline in 2015, the quantity of herbal 
cannabis seized has increased in many countries. The 
overall increase between 2016 and 2017 is mainly due to 
substantial increases reported in Greece, Spain and in 
particular Italy. Every year since 2009, Turkey has seized 
more herbal cannabis than any EU country, but in 2017, 
the amount of herbal cannabis seized in Italy almost 
equalled that seized in Turkey. In addition, a number of 
countries that generally seize small quantities of herbal 
cannabis also showed considerable increases in 2017. 
One example is Hungary, where the quantity seized was 
7 times the amount seized in the previous year (over 
3.5 tonnes in 2017, 0.5 tonnes in 2016).
Seizures of cannabis plants may be regarded as an 
indicator of the production of the drug within a country. 
However, differences between countries, both in law 
enforcement priorities and reporting practices, mean the 
data must be interpreted with caution. The number of 
plants seized in Europe peaked at 7 million in 2012, due to 
intensive interdiction in Italy that year, before dropping to 
2.5 million plants in 2015, and increasing to 3.4 million 
plants in 2017. In 2017, European countries reported 490 
seizures of cannabis oil, with Turkey (50 litres in 3 seizures) 
and Greece (12 kg in 37 seizures) accounting for the 
largest quantities.
Analysis of indexed trends among those countries 
consistently reporting price and potency data shows an 
increase in the potency of both herbal cannabis and 
cannabis resin since 2007. Resin potency has shown 
a continuous increase since 2009. Drivers of this 
increasing average potency in resin likely include the 
introduction of high-potency plants and new production 
techniques in Morocco, and, to a lesser extent, the greater 
use within Europe of resin extraction techniques that 
provide higher potency products. The average potency of 
herbal cannabis increased in 2017, after a period of 
stability between 2013 and 2016. However, it remains to 
be seen if this recent increase is the start of a new trend. 
Data suggest that the retail price per gram is similar for 
resin and herbal cannabis and that the prices have 
remained stable since about 2009.
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Availability of low-THC cannabis products
Since 2017, herbal cannabis and cannabis oils have been 
offered for open sale in health food shops or specialist 
shops in several EU countries. Sales have taken place 
based on the claim that these products have little or no 
intoxicating effect and therefore are not controlled under 
drug laws.
Herbal cannabis and its extracts are known for the two 
cannabinoids tetrahydrocannabinol (THC) and cannabidiol 
(CBD). THC can cause intoxicating effects, while CBD has 
been associated with health benefits, though at present 
there is little evidence for most conditions that have been 
studied. The percentage of each can vary greatly in 
cannabis plants. The EU common agricultural policy 
subsidises growing certain varieties of the cannabis plant 
for industrial uses, provided their THC content does not 
exceed 0.2 % (a limit originally intended to distinguish 
between plant types, not a safety profile for human 
consumption). National limits may be between 0 and 
0.3 %.
The new products are claimed to have less than 0.2 % or 
0.3 % THC and seem to fit broadly into two categories, 
which may overlap. The first is marketed to existing illicit 
cannabis users as ‘legal’ cannabis, in formats usually 
associated with smoking. The second is marketed with 
‘health’ and ‘well-being’ associations, emphasising the 
content of CBD, often in the form of oils or creams. The 
categories are also reflected in the type and decor of their 
sales outlets. As there is no agreed testing standard 
established for these products, the THC and CBD content 
may vary from that stated on the labels or on the ‘test 
results’ that may be displayed with the product.
FIGURE 1.3
Trends in the number of cannabis seizures and quantity of cannabis seized: resin and herb
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Heroin: quantity seized increases
Heroin is the most common opioid on the EU drug market. 
Historically, imported heroin has been available in Europe 
in two forms, the more common of which is brown heroin 
(its chemical base form), produced mainly from morphine 
extracted from poppies grown in Afghanistan. Far less 
common is white heroin (a salt form), which in the past 
came from South-East Asia, but now may also be 
produced in Afghanistan or neighbouring countries. Other 
opioids available in illicit markets in Europe include opium 
and the medicines morphine, methadone, buprenorphine, 
tramadol and various fentanyl derivatives. Some of these 
opioids may be diverted from legitimate pharmaceutical 
supplies, while others are illegally manufactured.
Afghanistan remains the world’s largest illicit producer of 
opium, and most heroin found in Europe is thought to be 
manufactured there or in neighbouring Iran or Pakistan. 
Illicit opioid production in Europe has until recently been 
limited to homemade poppy products produced in some 
eastern countries. The discovery of laboratories producing 
heroin from morphine using acetic anhydride in Bulgaria, 
Czechia, Spain and the Netherlands in recent years, 
together with an increase in morphine and opium seizures, 
suggests that some heroin is now manufactured closer to 
consumer markets in Europe. This change may reflect 
suppliers seeking to reduce costs by carrying out the last 
stages of heroin production in Europe, where precursors 
such as acetic anhydride are cheaper than in opium-
producing countries. Manufacturing the drug close to the 
consumer market may also be aimed at reducing 
interdiction risks.
Heroin enters Europe along four main trafficking routes. 
The two most important ones are the ‘Balkan route’ and 
the ‘southern route’. The first and most significant of these 
runs through Turkey, into Balkan countries (Bulgaria, 
Romania or Greece) and on to central, southern and 
western Europe. An offshoot of the Balkan route involving 
Syria and Iraq has also emerged. The southern route, 
where shipments from Iran and Pakistan enter Europe by 
air or sea, either directly or transiting through African 
countries, has gained importance in recent years. Other 
routes include the ‘northern route’ from Afghanistan 
through Central Asia to Russia and a route through the 
southern Caucasus and across the Black Sea.
A period of reduced heroin availability was observed in 
a number of European countries around 2010/11, 
accompanied by an overall drop in both numbers of 
seizures and quantities of heroin seized. Since then, 
seizures in the European Union have largely stabilised, 
with 37 000 seizures amounting to 5.4 tonnes reported in 
2017. Turkey continues to seize more heroin than all other 
European countries combined (Figure 1.4). Following 
a steep drop in seizures in the period 2014-16, from 12.8 
to 5.6 tonnes, in 2017 Turkey seized 17.4 tonnes of heroin, 
the largest quantity for a decade.
Among those countries consistently reporting price and 
purity data, indexed trends suggest that, following a sharp 
decrease between 2009 and 2011, heroin purity increased 
rapidly before stabilising in recent years, but below 2007 
levels. In contrast, overall the retail price of heroin declined 
slightly over the last decade, with a decline also seen in 
2017.
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In addition to heroin, other opioid products are seized in 
European countries. Although these represent a small 
fraction of total opioid seizures, they increased markedly in 
2017. The other opioids most commonly seized include 
the medicinal opioids tramadol, buprenorphine and 
methadone (see Table 1.1). In 2017, for the second year 
running, increases were reported in the quantities seized 
of tramadol and fentanyl derivatives. Furthermore, the 
quantities of opium and morphine seized were also much 
higher in 2017 than in the previous year.
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TABLE 1.1
Seizures of opioids other than heroin in 2017
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Opioid Number Quantity Number 
of countriesKilograms Litres Tablets Patches
Methadone 1 428 17.2 26.4 30 381 18
Buprenorphine 2 649 0.5 0.01 58 682 17
Tramadol 4 290 13.8 0.1 118 935 898 11
Fentanyl derivatives 940 14.3 1.9 10 551 2 291 13
Morphine 358 246.0 1.3 9 337 13
Opium 1 837 2 177.9 17
Codeine 522 0.1 18 475 8
Dihydrocodeine 21 1 436 4
Oxycodone 560 0.0001 18 035 8
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Europe’s stimulant market: regional differences
The main illicit stimulant drugs available in Europe are 
cocaine, amphetamine, methamphetamine and MDMA. 
There are marked regional differences regarding what 
stimulant is most commonly seized (Figure 1.5), which are 
influenced by the location of entry ports and trafficking 
routes, major production centres and large consumer 
markets. Cocaine is the most frequently seized stimulant 
in many western and southern countries, while 
amphetamines and MDMA seizures are predominant in 
northern and eastern Europe.
Cocaine market: seizures at historical high
In Europe, cocaine is available in two forms, the most 
common is cocaine powder (the salt form) and less 
commonly available is crack cocaine (free base), 
a smokable form of the drug. Cocaine is produced from the 
leaves of the coca bush, which is cultivated mainly in 
Colombia, Bolivia and Peru. Cocaine is transported from 
diverse departure points in South and Central America to 
Europe by various means, including passenger flights, air 
freight, private aircraft, yachts and other small vessels. 
However, the largest quantity appears to be smuggled in 
maritime freight, especially containers. The Caribbean, 
West and North Africa are important transit zones for 
cocaine coming to Europe.
In 2017, the number of cocaine seizures and the quantity 
seized in the European Union reached the highest levels 
ever recorded, with more than 104 000 seizures of cocaine 
reported, amounting to 140.4 tonnes. The quantity of 
cocaine seized surpassed the previous high, recorded in 
2006, by more than 20 tonnes and represented a doubling 
of the quantity seized in 2016 (see Figure 1.6). With 
combined seizures of around 86 tonnes, Belgium (45 
tonnes) and Spain (41 tonnes) accounted for 61 % of the 
estimated EU total in 2017, but large quantities were also 
reported by France (17.5 tonnes) and the Netherlands 
(14.6 tonnes). In addition, the purity of cocaine at retail 
level has been increasing since 2010, particularly in 2016 
and 2017, when it reached the highest level in the last 
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decade. The retail price of cocaine has remained stable. 
Taken together, these indicators suggest that cocaine 
availability is at an all-time high.
Seizures of crack cocaine are low and stable in the 
countries that report them. This may be explained in part 
because crack is manufactured within Europe, close to the 
consumer markets, and is not transported across borders, 
where many drug seizures usually take place.
The number and quantity of seizures of coca leaves has 
been increasing, totalling 204 kilograms of coca leaves in 
2017 alongside a small amount of coca paste. This may 
indicate a diversification in production tactics by some 
criminal organisations, as the cocaine laboratories found in 
Europe in the past have mainly been ‘secondary extraction 
facilities’, where cocaine is recovered from materials in 
which it has been incorporated (such as wines, clothes, 
plastics), rather than laboratories processing coca leaves.
Number of powder cocaine seizures and quantity seized: trends and 2017 or most recent year
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Drug production: precursor chemical developments
Drug precursors are chemicals needed to manufacture 
illicit drugs. Historically, in Europe the main area of concern 
has been in relation to precursors for the production of 
synthetic drugs such as amphetamine, methamphetamine 
and MDMA. However, the emergence of heroin laboratories 
in the EU has placed a greater emphasis on the diversion 
of acetic anhydride, the precursor involved in the 
conversion of morphine to heroin. As many of these 
precursor chemicals have legitimate uses they are not 
prohibited, but their trade is monitored and controlled 
through EU regulations, which schedule certain chemicals. 
The availability of precursors and other chemicals 
necessary for drug production has a large impact on the 
drug market and on the production methods used in illicit 
laboratories. Production techniques are also evolving over 
time in order to avoid detection, controls and penalties, 
and changes typically include the use of alternative 
substances to produce synthetic drugs or their precursors, 
which then becomes the favoured production method. The 
additional processing associated with the use of these 
alternative substances, and more complex routes of 
synthesis, can require more chemicals, creating more 
waste, potentially leading to greater environmental 
damage if this is disposed of inappropriately.
Data on seizures and stopped shipments of drug 
precursors confirm the use of both scheduled and non-
scheduled chemicals in the production of illicit drugs in the 
European Union, in particular for amphetamines and 
MDMA (Table 1.2). The scheduling of the BMK (benzyl 
methyl ketone) precursor APAAN (alpha-
phenylacetoacetonitrile) in late 2013 continues to have an 
impact, with seizures falling from 48 tonnes in 2013 to 
around 5 tonnes in 2017. Seizures of the alternative 
chemical APAA (alpha-phenylacetoacetamide) increased 
sharply in 2016 and again in 2017. Seizures of glycidic 
derivatives of BMK, which can also be easily converted to 
BMK, first reported in 2015, also increased sharply to 
about 3 tonnes in 2016, and further to almost 6 tonnes 
in 2017.
The quantities of PMK (piperonyl methyl ketone) and 
non-scheduled chemicals for MDMA manufacture seized 
increased dramatically in 2017. All seizures of PMK and 
most seizures of the glycidic derivatives of PMK in 2017 
occurred in the Netherlands. In addition, large amounts of 
2-bromo-4-methylpropiophenone, a precursor for synthetic 
cathinones, as well as large amounts of BMK (and glycidic 
derivatives of BMK) were seized in the Netherlands, 
confirming the country’s central role in synthetic drug 
production in the European Union.
Seizures Stopped shipments TOTALS
Scheduled/non-scheduled Number Quantity Number Quantity Number Quantity
MDMA or related substances
PMK (litres) 10 5 397 0 0 10 5 397
Safrole (litres) 5 2 969 0 0 5 2 969
Piperonal (kg) 3 37 4 6 384 7 6 421
Glycidic derivatives of PMK (kg) 20 17 774 0 0 20 17 774
N-t-BOC-MDMA (kg) 1 25 0 0 1 25
Amphetamine and methamphetamine
BMK (litres) 29 3 506 0 0 29 3 506
Ephedrine bulk (kg) 14 25 0 0 14 25
Pseudoephedrine bulk (kg) 23 13 0 0 23 13
APAAN (kg) 9 5 065 0 0 9 5 065
PAA, phenylacetic acid (kg) 0 0 4 300 4 300
APAA (kg) 90 10 830 0 0 90 10 830
Glycidic derivatives of BMK (kg) 5 5 725 0 0 5 5 725
Others
Acetic anhydride (litres) 24 81 289 55 243 011 79 324 300
2-bromo-4-methylpropiophenone (kg) 4 1 211 0 0 4 1 211
N-phenethyl-4-piperidone (kg) 2 4.5 0 0 2 4.5
TABLE 1.2
Summary of seizures and stopped shipments of EU scheduled precursors and non-scheduled chemicals used for selected drugs produced in 
the European Union, 2017
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In 2017, more than 81 tonnes of acetic anhydride was 
seized and a further 243 tonnes was stopped before their 
supply, which represents a large increase compared to the 
previous years. Furthermore, it is worth noting that 
a significant amount of N-phenethyl-4-piperidone, 
a precursor for the manufacture of fentanyl derivatives, has 
been reported seized by Estonia.
Amphetamine and methamphetamine seizures: 
signs of gradual increase
Amphetamine and methamphetamine are synthetic 
stimulant drugs, which may be grouped together as 
‘amphetamines’ in some datasets. Over the last decade, 
seizure data indicate that the availability of 
methamphetamine has been slowly increasing and 
spreading geographically, but it is still much lower than 
that of amphetamine.
Both drugs are produced in Europe for the European 
market. The available data indicate that amphetamine 
production takes place mainly in Belgium, the Netherlands 
and Poland, and to a lesser extent in the Baltic States and 
Germany. Typically, all stages of amphetamine production 
are carried out in the same location. Seizures of 
amphetamine oil in some Member States, however, 
indicate that this product may be trafficked between 
countries, with the final stage of production occurring at, 
or near, its intended destination point.
Some amphetamine is also manufactured in the European 
Union for export, principally to the Middle East. Large 
seizures of amphetamine tablets with a ‘captagon’ logo 
that have been seized in Turkey are linked with Syria.
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Methamphetamine seized in Europe is mainly produced in 
Czechia and the border areas of neighbouring countries. 
A small number of illicit methamphetamine laboratories 
are found each year in the Netherlands, and sometimes 
these are quite large facilities, mainly producing for 
markets in the Far East and Oceania. In Czechia, 
methamphetamine is produced mainly from 
pseudoephedrine, which is extracted from medicinal 
products. In 2017, of the 298 illegal methamphetamine 
laboratories reported in the European Union, 264 were 
located in Czechia. Small-scale laboratories operated by 
local user-dealers supplying the domestic market 
dominate. However, larger-scale facilities involving 
non-Czech organised crime groups producing 
methamphetamine for other European countries have 
emerged in recent years.
In 2017, EU Member States reported 35 000 seizures of 
amphetamine, amounting to 6.4 tonnes. The estimated 
quantity of amphetamine seized in the European Union 
has generally fluctuated around 5 to 6 tonnes each year 
since 2010, although there have been increases in each of 
the past 2 years (Figure 1.7). Germany and the United 
Kingdom generally seize the largest amounts, often more 
than a tonne each. Methamphetamine seizures are far 
lower, with 9 000 seizures reported in the European Union 
in 2017, amounting to 0.7 tonnes, with France (122 kg), 
Germany (114 kg) and Czechia (93 kg) seizing the largest 
amounts (Figure 1.8). The number of seizures of 
methamphetamine has shown an overall upward trend 
since 2002 but with signs of stabilisation in recent years; 
the quantity seized has been increasing, albeit with some 
fluctuation, since 2009.
In 2017, Turkey seized more amphetamine (6.6 tonnes) 
than the EU Member States combined (6.4 tonnes). 
Almost all of the amphetamine seized in Turkey was in the 
form of tablets (26.3 million tablets — over 99.5 % of the 
total estimated amount seized), including large quantities 
of ‘captagon’ tablets containing amphetamine. Turkey also 
seized an exceptionally large quantity of 
methamphetamine in 2017 (658 kg), a similar amount to 
that reported for the European Union (662 kg).
Compared with a decade ago, both the price and purity of 
amphetamine in Europe were higher in 2017, despite 
a slight fall compared to the previous year. Typically, both 
the average reported purity and price are higher for 
methamphetamine than for amphetamine samples.
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MDMA: increased production and seizures
MDMA (3,4-methylenedioxymethamphetamine) is 
a synthetic drug chemically related to amphetamine, but 
with different effects. MDMA is consumed as tablets, often 
called ecstasy, or in powder and crystal form. International 
efforts to control drug precursors — chemicals necessary 
for the production of illicit drugs — disrupted the MDMA 
market in the late 2000s. More recently, the MDMA market 
has seen a revival, as producers have found substitute, 
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non-controlled chemicals for use in the manufacture of the 
drug. This is reflected in the average MDMA content of 
tablets, among those countries routinely reporting data, 
which has been increasing since 2010 and reached 
a 10-year high in 2017. Marketing appears to play a role in 
sales, and new tablet designs in various colours, shapes 
and brand logos are constantly being introduced.
The production of MDMA in Europe is mainly concentrated 
in the Netherlands and Belgium. A total of 21 active MDMA 
laboratories, almost double the number in 2016, were 
reported to have been dismantled in the European Union 
in 2017, all in the Netherlands. In Belgium, although no 
MDMA production facilities were detected in 2017, reports 
of the dumping of chemical waste from MDMA production 
suggest that the drug continues to be produced there.
Seizure reports from outside Europe, identified through the 
monitoring of open source information, and analysis of 
darknet market data illustrate the important role played by 
European producers in the global supply of MDMA. For 
example, darknet market monitoring data show that as well 
as facilitating direct sales to consumers, these markets are 
used by dealers across the globe to purchase MDMA 
produced in Europe. Analysis shows that transactions 
involving quantities of MDMA tablets indicative of the 
middle level of the market account for more than double 
the revenue of sales of retail-level quantities. In contrast, 
darknet cannabis and cocaine transactions are 
overwhelmingly at the retail level.
The number of reported MDMA seizures in the European 
Union has been on an upward trend since 2010. The 
quantity of MDMA seized is more often reported in number 
of tablets than by weight. The estimated 6.6 million MDMA 
tablets reported seized in 2017 is the highest number in 
the European Union since 2007. Fluctuations can be seen 
in the long term in the number of MDMA tablets seized 
annually in the European Union, reflecting in part the 
impact of large individual seizures. Some countries have 
also reported seizures of MDMA powder. Reported seizures 
of MDMA powder in the European Union increased from 
0.3 tonnes in 2016 to 1.7 tonnes in 2017. This increase is 
mainly due to seizures reported by the Netherlands — 
a country now able to provide data on the quantity of 
MDMA seized, for the first time in 5 years, and thus 
contributing to a more comprehensive analysis in this area.
Large quantities of MDMA tablets were seized in Turkey in 
2017, more than double the amount in the previous year, 
amounting to 8.6 million tablets and exceeding the total 
amount seized in the European Union (Figure 1.9).
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Seizures of LSD, GHB and ketamine
Seizures of other illicit drugs are reported in the European 
Union, including over 2 000 seizures of LSD (lysergic acid 
diethylamide) in 2017, amounting to 74 000 units. The 
overall number of LSD seizures has more than doubled 
since 2010, although the quantity seized has fluctuated. 
Sixteen EU countries reported around 2 000 seizures of 
ketamine, amounting to an estimated 194 kilograms and 
5 litres of the drug, most of which was accounted for by 
Belgium, France and the United Kingdom. Norway also 
reported a small number of ketamine seizures — 42 
seizures amounting to 0.1 kilogram. In 2017, seizures of 
GHB (gamma-hydroxybutyrate) or GBL (gamma-
butyrolactone) were reported by 14 EU countries, Norway 
and Turkey, with Norway accounting for over a quarter of 
the total number of seizures. Taken together, the estimated 
1 600 seizures amounted to almost 127 kilograms and 
1 300 litres of the drug. Belgium seized almost half of the 
total quantity, mainly as GBL.
New psychoactive substances: a complex market
By the end of 2018, the EMCDDA was monitoring more 
than 730 new psychoactive substances, 55 of which were 
detected for the first time in Europe in 2018. These 
substances make up a broad range of drugs, such as 
synthetic cannabinoids, stimulants, opioids and 
benzodiazepines.
In most cases, new psychoactive substances are produced 
in bulk quantities by chemical and pharmaceutical 
companies in China. From there they are shipped to 
Europe, where they are processed into products, packaged 
and sold. They are sometimes sold openly in physical 
shops. Although restrictions have limited the open sale of 
these products in some countries, they may still be 
available more covertly. They can also be obtained through 
online shops or the darknet or may be sold on the illicit 
drug market. In such cases, they may be sold under their 
own name or sold as or mixed with other drugs, such as 
heroin, cocaine, MDMA or psychoactive medicines.
The number of new substances identified for the first time 
each year peaked in 2014-15, but has since stabilised at 
levels comparable to 2011-12 (Figure 1.10). The causes of 
this are unclear, but they may reflect the results of 
sustained efforts to control new substances in Europe, as 
well as legislative initiatives in China.
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The number of new substances detected for the first time 
each year is just one of a range of metrics that the 
EMCDDA uses in order to understand the overall market. 
For example, 390 substances, approximately half of the 
new substances being monitored by the EU Early Warning 
System, were detected in Europe in 2017, some of which 
first appeared more than 10 years ago. This illustrates the 
dynamic nature of this part of the drug market: substances 
may appear and then disappear rapidly, but the number of 
substances in circulation remains high.
Seizures of new psychoactive substances
During 2017, law enforcement agencies from across 
Europe reported close to 64 160 seizures of new 
psychoactive substances to the EU Early Warning System. 
Of these, 39 115 seizures were reported by the 28 EU 
Member States (Figure 1.11).
In 2017, new psychoactive substances were most 
commonly reported as powders, which amounted to 
2.8 tonnes, across all categories. This is broadly 
comparable to the figures from previous years. In addition, 
just under 240 kilograms of herbal material were reported, 
two-thirds of which was in the form of smoking mixtures 
containing synthetic cannabinoids. New substances were 
also found in tablets (6 769 cases, 2.8 million units), 
blotters (980 cases, 23 000 units) and liquids (1 430 cases, 
490 litres). Some of these liquids were sold as ready-to-use 
nasal sprays as well as e-liquids for vaping in e-cigarettes.
In Europe, seizures of new psychoactive substances are 
typically dominated by synthetic cannabinoids and 
cathinones. However, more diversity can be seen in recent 
years, with other groups of substances becoming more 
prominent. For example, the quantity of opioids and 
benzodiazepines seized in Europe appears to have 
increased.
Seizures reported to the EU Early Warning System: trends in total number of seizures and number of seizures by category in 2017
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New synthetic opioids
Since 2009, 49 new synthetic opioids have been detected 
on Europe’s drug market — including 11 reported for the 
first time in 2018. The overall figure includes 34 fentanyl 
derivatives, 6 of which were reported for the first time in 
2018. Although currently playing a small role in Europe’s 
drug market, many new opioids (particularly those of the 
fentanyl family) are highly potent substances that pose 
a serious threat to individual and public health.
In 2017, approximately 1 300 seizures of new opioids were 
reported to the EU Early Warning System by law 
enforcement agencies. The majority of these cases (70 %) 
were seizures of fentanyl derivatives (Figure 1.12), but 
a number of other types of opioids (such as U-47,700 and 
U-51,754) were also reported. The total quantity of opioid 
powders and tablets reported has seen a continued 
increase since 2012 (Figure 1.12). Overall, seizures of new 
opioids in 2017 amounted to approximately 17 kilograms 
of powders, 1.8 litres of liquids and over 29 000 tablets. 
Less commonly, new opioids have also been found in 
blotters and in herbal smoking mixtures; in these cases, 
there may be no indication that they contain potent 
opioids, which could pose a risk of poisoning to people 
who use them, particularly if they have no existing 
tolerance to opioids.
Of particular concern have been the seizures of carfentanil 
in Europe, one of the most potent opioids known. In 2017, 
over 300 seizures of carfentanil were reported in Europe. 
These seizures amounted to approximately 4 kilograms of 
powders and 250 millilitres of liquids. Some of these 
powders were sold as or mixed with heroin.
New benzodiazepines
Over the last few years there appears to have been an 
increase in the number, type and availability of new 
psychoactive substances belonging to the benzodiazepine 
class, which are not controlled under international drug 
control laws. Some of these are sold as fake versions of 
commonly prescribed anti-anxiety medicines such as 
alprazolam (Xanax) and diazepam, making use of existing 
distribution networks in the illicit drug market. Others are 
sold online, sometimes under their own names, marketed 
as ‘legal’ versions of authorised medicines.
The EMCDDA is currently monitoring 28 new 
benzodiazepines — 23 of which were first detected in 
Europe in the last 5 years. In 2017, close to 3 500 seizures 
of new benzodiazepines were reported to the EU Early 
Warning System. Most of these seizures were of tablets, 
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amounting to more than 2.4 million units, which represents 
a large increase from the around half a million tablets 
reported in 2016. This increase can be attributed to large 
seizures of etizolam — a substance first reported to the 
Early Warning System in 2011 — in one country. In 
addition, around 27 kilograms of powders, 1.4 litres of 
liquids and 2 400 blotters containing new benzodiazepines 
were reported to have been seized in 2017.
New psychoactive substances: 
new legal responses
European countries take measures to prevent the supply of 
drugs under three United Nations Conventions, which 
provide a framework for control of production, trade and 
possession of over 240 psychoactive substances. The 
rapid emergence of new psychoactive substances and the 
diversity of available products has proved challenging for 
the Conventions and for European policymakers and 
lawmakers.
At national level, various measures have been used to 
control new substances, and three broad types of legal 
response can be identified. Many countries in Europe first 
responded by using consumer safety legislation, and 
subsequently extended or adapted existing drug laws to 
incorporate new psychoactive substances. Increasingly, 
countries have designed specific new legislation to 
address this phenomenon.
For many years, most European countries only listed 
controlled substances individually. However, as the 
number of new substances detected in Europe increased, 
FIGURE 1.13
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more countries have sought to control groups of 
substances. Most of the countries have defined the groups 
by chemical structure (‘generic’ groups), though a few 
have defined the groups by the effects. Most of the 
countries that have taken the generic approach have 
added the group definitions to existing drug laws, but 
some have only included such groups in specific new 
psychoactive substance legislation.
At EU level, the legal framework for responding to public 
health and social threats caused by new psychoactive 
substances, which dated from 2005, has been revised, 
with the aim of establishing a swifter, more effective 
system (Figure 1.13). The new legislation retains the 
three-step approach to responding to new psychoactive 
substances — early warning, risk assessment and control 
measures — while strengthening existing processes by 
streamlining and accelerating data-collection and 
assessment procedures, and introducing shorter 
deadlines. Following the risk assessment, the Commission 
can then make a proposal for subjecting the substance to 
control measures. The European Parliament and the 
Council have the right, within 2 months and under certain 
conditions, to object to the Commission proposal. National 
authorities will have 6 months (instead of 12) to place the 
substance under control on their territory once the 
decision enters into force. This new legislation is 
applicable across Europe from 23 November 2018.
Drug law offences: cannabis predominates
The implementation of laws is monitored through data on 
reported drug law offences. The numbers reflect 
differences in national legislation and priorities and also 
the different ways in which the laws are applied and 
enforced.
In 2017, an estimated 1.5 million drug law offences were 
reported in the European Union, an increase of about 
a fifth (20 %) since 2007. Most of these offences (79 %) 
related to use or possession, totalling around 1.2 million 
offences, a 27 % increase compared with 10 years ago. 
Drug use or possession offences involving cannabis 
continued to increase. Three-quarters (75 %) of use or 
possession offences involved cannabis, although this 
figure fell by 2 percentage points compared with 2016. The 
upward trend in offences for MDMA use or possession 
continued in 2017, although they still only account for 2 % 
of use-related offences (Figure 1.14).
Overall, the number of drug supply offences in the 
European Union has increased by 22 % since 2007, with 
an estimate of more than 230 000 cases in 2017. Again, 
cannabis dominates, accounting for the majority of supply 
offences (57 %). Reports of supply offences for MDMA 
have been rising since 2011 (Figure 1.14), whereas 
offences related to the supply of heroin have decreased 
slightly while the situation for cocaine is relatively stable 
over the same period.
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Drug use prevalence 
and trends
Drug use in Europe now encompasses 
a wider range of substances than in the 
past. Among people who use drugs, 
polydrug consumption is common and 
individual patterns of use range from 
experimental to habitual and dependent 
consumption. Cannabis is the most 
commonly used drug — the prevalence 
of use is about five times that of other 
substances. While the use of heroin and 
other opioids remains relatively rare, 
these continue to be the drugs most 
commonly associated with the more 
harmful forms of use, including injecting 
drug use. The extent of stimulant use 
and the types that are most common 
vary across countries, and evidence is 
growing of a potential increase in 
stimulant injecting. Use of all drugs is 
generally higher among males, and this 
difference is often accentuated for more 
intensive or regular patterns of use.
Monitoring drug use
The EMCDDA collects and maintains datasets that 
cover drug use and patterns of use in Europe.
Surveys undertaken among school students and the 
general population can provide an overview of the 
prevalence of experimental and recreational drug 
use. These survey results are complemented by 
community level analyses of drug residues in 
municipal wastewater, carried out in cities across 
Europe.
Studies reporting estimates of high-risk drug use are 
used to identify the extent of the more entrenched 
drug use problems, while data on those entering 
specialised drug treatment systems, when 
considered alongside other indicators, inform an 
understanding on the nature and trends in high-risk 
drug use.
Other, more targeted data sources are also used 
here. These ‘leading edge’ indicators provide insights 
into changing drug-use patterns and types of drug 
used. While not representative of the general 
population, these sources provide timely 
supplementary data. All data sources on drug use 
have strengths and weaknesses, and both the 
availability and the quality of data can vary by 
country. This is why the EMCDDA takes a cautious 
and multi-indicator approach to describing the 
European drug situation.
Full data sets and methodological notes can be 
found in the online Statistical Bulletin.
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Around 96 million adults have used illicit drugs
Around 96 million or 29 % of adults (aged 15-64) in the 
European Union are estimated to have tried illicit drugs 
during their lives. Experience of drug use is more 
frequently reported by males (57.8 million) than females 
(38.3 million). The most commonly tried drug is cannabis 
(55.4 million males and 36.1 million females), with much 
lower estimates reported for the lifetime use of cocaine 
(12.4 million males and 5.7 million females), MDMA 
(9.3 million males and 4.6 million females) and 
amphetamines (8.3 million males and 4.1 million females). 
Levels of lifetime use of cannabis differ considerably 
between countries, ranging from around 4 % of adults in 
Malta to 45 % in France.
Last year drug use provides a measure of recent drug use 
and is largely concentrated among young adults. An 
estimated 19.1 million young adults (aged 15-34) used 
drugs in the last year (16 %), with about twice as many 
males (20 %) as females (11 %) reporting doing so.
Cannabis use among young people
Across all age groups, cannabis is the illicit drug most 
commonly used. The drug is generally smoked and, in 
Europe, it is commonly mixed with tobacco. Patterns of 
cannabis use can range from the occasional to the regular 
and dependent.
It is estimated that 91.2 million adults in the European 
Union (aged 15-64), or 27.4 % of this age group, have tried 
cannabis during their lives. Of these, an estimated 
17.5 million young adults (aged 15-34), or 14.4 % of this 
age group, used cannabis in the last year. Last year 
prevalence rates among young adults range from 3.5 % in 
Hungary to 21.8 % in France. Among young people using 
cannabis in the last year, the ratio of males to females is 
two to one. When only 15- to 24-year-olds are considered, 
the prevalence of cannabis use is higher, with 18 % 
(10.1 million) having used the drug in the last year and 
9.3 % in the last month (5.2 million).
Last year prevalence of cannabis use among young adults (15-34): selected trends and most recent data
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In most countries, recent survey results show either stable 
or increasing last year cannabis use among young adults. 
Of the countries that have produced surveys since 2016 
and reported confidence intervals, 6 reported higher 
estimates, 5 were stable and 1 reported a decrease 
compared with the previous comparable survey. In 11 of 
these countries, an increase in use among 15- to 24-year-
olds has been reported in the most recent survey.
Few countries have sufficient survey data to permit 
statistical analysis of long-term trends in last year use of 
cannabis among young adults (15-34). Among these, the 
decreasing trends previously observed in Spain and the 
United Kingdom (England and Wales) have stabilised in 
the more recent data, although the United Kingdom has 
seen an increase to 12.3 % in the most recent year 
(Figure 2.1). Since 2000, increasing trends in last year 
prevalence of cannabis use among young adults have 
been observed in a number of countries. These include 
Ireland and Finland, where the most recent data indicate 
levels approaching the EU average of 14.4 % and, albeit at 
lower levels, Bulgaria and Romania. In France, recent 
surveys show prevalence levels are stable at a high level of 
22 %. In Denmark, a 2017 survey reported a decrease: to 
15.4 % from the 2013 estimate of 17.6 %.
Data from web surveys can provide complementary 
information to general population surveys and further 
insight into the use of drugs in Europe. While not 
representative of the general population, these surveys are 
able to reach large samples of people who use drugs. The 
European Web Survey on Drugs collected information 
about patterns of use and purchases of the most 
commonly used illicit drugs from 40 000 people who use 
drugs, recruited primarily through social media. The 
findings show that herbal cannabis was more commonly 
used than cannabis resin. However, many respondents 
reported using both types, particularly in France, Italy and 
the Netherlands. The use of cannabis resin only was 
reported infrequently (Figure 2.2).
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High-risk cannabis use: signs of stabilisation
Based on surveys of the general population, it is estimated 
that around 1 % of adults in the European Union are daily 
or almost daily cannabis users — that is, they have used 
the drug on 20 days or more in the last month. Around 
60 % of these are under 35 and around three-quarters are 
male.
When considered alongside other indicators, data on those 
entering treatment for cannabis problems can provide 
information on the nature and scale of high-risk cannabis 
use in Europe. In 2017, approximately 155 000 people 
entered drug treatment in Europe for problems related to 
cannabis use; of those, about 83 000 were entering 
treatment for the first time in their lives. In the 24 countries 
with available data, the overall number of first-time 
entrants for cannabis problems increased by 76 % 
between 2006 and 2017.
Overall, 47 % of the primary cannabis users entering 
treatment for the first time in 2017 reported daily use of 
the drug in the last month, with figures ranging from 10 % 
or less in Latvia, Hungary and Romania to 68 % or more in 
Spain, the Netherlands and Turkey.
Cocaine use: some signs of an increase
Cocaine is the most commonly used illicit stimulant drug 
in Europe, and its use is more prevalent in southern and 
western countries. In recent years the use of this drug has 
been on the increase in Europe. For research and 
monitoring purposes, people who use cocaine may be 
categorised in different ways, according to the setting, the 
product used or the motivation for using. Among regular 
consumers, a broad distinction can be made between 
typically more socially integrated users, who sniff powder 
cocaine (cocaine hydrochloride), and marginalised users, 
who inject cocaine or smoke crack (cocaine base), 
sometimes alongside the use of opioids. In many datasets, 
it is not possible to distinguish between the two forms of 
cocaine (cocaine powder or crack) and the term cocaine 
use covers both.
It is estimated that 18.0 million adults in the European 
Union (aged 15-64), or 5.4 % of this age group, have tried 
cocaine during their lives. Among these are about 
2.6 million young adults aged 15 to 34 (2.1 % of this age 
group) who have used the drug in the last year.
Six countries, Denmark, Ireland, Spain, France, the 
Netherlands and the United Kingdom, report last year 
prevalence of cocaine use among young adults of more 
than 2.5 % (Figure 2.3). Of the countries that have 
produced surveys since 2016 and reported confidence 
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intervals, 3 reported higher estimates and 9 had stable 
estimates compared with the previous comparable survey.
A statistical analysis of long-term trends in last year use of 
cocaine among young adults is only possible for a small 
number of countries, among which there is some evidence 
of increased use: the annual survey in the United Kingdom 
reported an increase to 4.7 % after a period of relative 
stability; the fourth comparable annual survey from the 
Netherlands confirmed an upward trend, reaching 4.5 %; 
and in France an upward trend continued, rising above 3 % 
for the first time. In contrast, Spain continued to report 
a decline in prevalence, which fell to 2.8 % (Figure 2.3).
A 2018 EMCDDA trendspotter study, analysing multiple 
data sources, reported that the increase in the availability 
of higher-purity cocaine on Europe’s drug markets may be 
leading to a resurgence in the use of the drug in some 
countries. The study also highlighted signs that cocaine is 
expanding into new markets in eastern Europe, where the 
drug was previously little used.
Analysis of municipal wastewater for cocaine residues 
carried out in a multi-city study complements the results 
from population surveys. Wastewater analysis reports on 
collective consumption of pure substances within 
a community, and the results are not directly comparable 
with prevalence estimates from national population 
surveys. The results of wastewater analysis are presented 
in standardised amounts (mass loads) of drug residue per 
1 000 population per day. While they may be informative 
on the volume of cocaine used in a particular location, they 
do not provide direct information on the number of users.
A 2018 analysis found the highest mass loads of 
benzoylecgonine — the main metabolite of cocaine — in 
cities in Belgium, Spain, the Netherlands and the United 
Kingdom. Very low levels were found in the majority of the 
eastern European cities studied (see Figure 2.4), but the 
most recent data show signs of increases. Comparison 
with data from the previous year shows a picture 
suggesting generally increasing use. Of the 38 cities that 
have data for 2017 and 2018, 22 reported an increase, 5 
a decrease and 11 a stable situation. Increasing longer-
term trends are reported for most of the 13 cities with data 
for 2011 and 2018.
Last year prevalence of cocaine use among young adults (15-34): selected trends and most recent data
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Data from the European Web Survey on Drugs provide 
insights into the patterns of cocaine use among different 
groups and how this may vary between countries. When 
comparing amounts used across countries, it is important 
to note that both the price and purity of cocaine on the 
market will differ between countries and this may have an 
impact on amounts used. Among respondents who 
reported using cocaine, the proportion using the drug 
frequently (on more than 50 days in the last year) ranged 
from none at all in Czechia to over 10 % in Belgium, 
Cyprus, France, Italy and Luxembourg (Figure 2.5). 
Cocaine consumption varied between countries, ranging 
from an average of 1.3 grams per day of use in Austria, 
Belgium and France to 3.5 grams in Cyprus. In general, 
frequent users consumed higher amounts of the drug 
each day of use compared with less frequent users.
High-risk cocaine use: recent treatment demand 
increases in many countries
The prevalence of high-risk cocaine use among adults in 
Europe is difficult to gauge as only 4 countries have recent 
estimates. In addition, these estimates are not directly 
comparable, as they have been generated using different 
definitions and methodologies. In Spain, a new general 
population survey used high frequency of use to estimate 
high-risk cocaine use at 0.3 % among people aged 15-64 
in 2017/18. In 2015, based on Severity of Dependence 
Cocaine residues in wastewater in selected European cities: trends and most recent data
NB: Mean daily amounts of benzoylecgonine in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year 
from 2011 to 2018.
Source: Sewage Analysis Core Group Europe (SCORE).
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Frequency of cocaine use among participants in a web survey who 
reported use of the drug in the last year
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Scale questions, Germany estimated high-risk cocaine use 
among the adult population at 0.2 %. In 2017, using 
treatment and criminal justice data, Italy estimated that 
0.69 % of the adult population could be classified as 
high-risk cocaine users. In France, a 2017 capture-
recapture study estimated the prevalence of high-risk 
crack cocaine use at 0.07 %.
Spain, Italy and the United Kingdom account for almost 
three-quarters (73 %) of all reported specialised treatment 
entries related to cocaine in Europe. Overall, cocaine was 
cited as the primary drug by around 73 000 clients 
entering specialised drug treatment in 2017 and by more 
than 33 000 first-time clients.
After a period of decline, the overall number of cocaine 
first-time treatment entrants increased by 37 % between 
2014 and 2017. While much of this increase is accounted 
for by Italy and the United Kingdom, a total of 19 countries 
reported increases during the same period. Overall, the 
latest European data reveal a lag of 11 years between first 
cocaine use, on average at the age of 23, and first 
treatment for cocaine-related problems, on average at the 
age of 34.
The majority of those entering specialised treatment for 
problems related to cocaine use are primary powder 
cocaine users (55 000 or 14 % of all drug clients in 2017). 
Most primary cocaine clients are seeking treatment for use 
of the drug on its own (46 % of all powder cocaine clients) 
or in combination with cannabis (20 %), alcohol (23 %) or 
other substances (10 %). This group is generally reported 
to be relatively socially well-integrated, with stable living 
conditions and regular employment compared to those 
entering treatment with opioid problems. This is not the 
case, however, for those entering treatment for primary 
crack cocaine use (11 000 clients or 3 % of all drug clients 
in 2017), who appear more marginalised. Most crack-
related treatment demands are reported by the United 
Kingdom (65 %). Many primary crack cocaine clients report 
heroin as a secondary problem drug. Since 2014 increases 
in the number of crack cocaine clients are reported in 
Belgium, Ireland, France, Italy, Portugal and the United 
Kingdom.
The use of cocaine in combination with heroin or other 
opioids is reported by 56 000 clients entering specialised 
drug treatment in Europe in 2017. This number represents 
16 % of all treatment entrants for whom both primary and 
secondary drug information is available.
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MDMA use: a mixed picture
MDMA (3,4-methylenedioxy-methamphetamine) is used in 
the form of tablets (often called ecstasy), and also as 
crystals and powders; tablets are usually swallowed, but 
crystal and powder forms of MDMA may be taken orally or 
snorted.
It is estimated that 13.7 million adults in the European 
Union (aged 15-64), or 4.1 % of this age group, have tried 
MDMA/ecstasy during their lives. Figures for more recent 
use among young adults suggest that 2.1 million young 
adults (15-34) used MDMA in the last year (1.7 % of this 
age group), with national estimates ranging from 0.2 % in 
Portugal and Romania to 7.1 % in the Netherlands 
(Figure 2.6). Prevalence estimates for those aged 15-24 
years are higher, with 2.3 % (1.3 million) estimated to have 
used MDMA in the last year.
Until recently, in many countries, MDMA prevalence had 
been on the decline from peak levels attained in the early 
to mid-2000s. In recent years, however, monitoring sources 
suggest a mixed picture with no clear trends. Among the 
countries that have produced new surveys since 2016 and 
reported confidence intervals, 4 reported higher estimates 
than in the previous comparable survey, 6 reported stable 
estimates, and 2 reported a lower estimate.
Where data exist for a statistical analysis of trends in last 
year use of MDMA among young adults, the more recent 
data show a mixed picture (Figure 2.6). In the United 
Kingdom, the most recent data show prevalence of use 
has bounced back after falls in 2015 and 2016 that in turn 
reversed the increase seen between 2012 and 2014. In 
Spain, the long-term trend remains downward, although 
recent values are stable. The most recent data show 
a continued upward trend in Bulgaria. Data from the 2017 
survey in the Netherlands confirm the high levels reported 
in the previous three annual surveys.
Last year prevalence of MDMA use among young adults (15-34): selected trends and most recent data
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A 2018 multi-city analysis found the highest mass loads of 
MDMA in the wastewater in cities in Belgium, Germany 
and the Netherlands (Figure 2.7). Of the 37 cities that have 
data for 2017 and 2018, 21 reported an increase, 9 
a stable situation and 7 a decrease. Looking at longer-term 
trends, in most cities with data for both 2011 and 2018 (10 
cities), wastewater MDMA loads were higher in 2018 than 
in 2011. In 2017, the sharp increases observed over the 
2011-16 period appeared to be stabilising. However, the 
most recent data in 2018 point to increases in most cities.
MDMA is often taken alongside other substances, 
including alcohol. Current indications suggest that, in 
higher-prevalence countries, MDMA is no longer a niche or 
subcultural drug limited to dance clubs and parties, but is 
used by a broad range of young people in mainstream 
nightlife settings, including bars and house parties. The 
European Web Survey on Drugs found that among people 
who had used MDMA in the previous year, the proportion 
reporting frequent use (more than 50 days in the past year) 
ranged from none at all in Cyprus to around 8 % in Austria 
and Croatia.
MDMA use is rarely cited as a reason for entering 
specialised drug treatment. In 2017, MDMA was reported 
by less than 1 % (around 1 700 cases) of treatment 
entrants in Europe, with France, Hungary, United Kingdom 
and Turkey accounting for 68 % of these.
MDMA residues in wastewater in selected European cities: trends and most recent data  
NB: Mean daily amounts of MDMA in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year from 2011 
to 2018.
Source: Sewage Analysis Core Group Europe (SCORE).
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Monitoring drug use in recreational settings: 
innovative methods
Studies consistently find that drug use is more commonly 
reported in surveys carried out in nightlife settings (like 
clubs, bars or music festivals) than among the general 
population. New means of monitoring drug use in 
recreational settings have emerged that do not rely solely 
on self-reported survey data, but utilise the chemical 
analysis of samples from a range of sources: biological 
samples such as breath, urine and hair samples; the 
content of drug amnesty bins; and the drugs submitted to 
drug checking facilities.
Results are available from 3 044 analyses of drug samples 
submitted by users to 9 drug checking services operating 
in 7 EU Member States, performed between January and 
July 2018 and compiled by the Trans-European Drug 
Information network (TEDI). About half of the samples 
were tested at music events and about half were tested in 
drop-in centres. There were twice as many cocaine 
samples submitted in drop-in centres, mostly in Spain, 
than at music events.
Overall, MDMA (tablet and powder forms), cocaine and 
amphetamine were the three drugs most frequently 
submitted for testing, although there was variation 
between countries. Amphetamine was rarely submitted for 
testing in Belgium and Portugal, but represented more 
than 25 % of the samples submitted in Italy and Austria. 
New psychoactive substances, mostly synthetic 
cathinones, represented only 3 % of all drugs submitted for 
testing, although some such as 4-CMC and 4-CEC 
(synthetic cathinones) were occasionally found as 
adulterants in samples submitted as MDMA (Figure 2.8).
Data on drug purity obtained from 8 drug checking 
services during the first half of 2018 confirm recent reports 
on the increased availability of high-purity MDMA and 
cocaine observed in drug markets in western Europe. The 
highest average dosage of MDMA in tablets tested in drug 
checking services was reported from Belgium (182 mg). 
Five services reported individual tablets containing high 
amounts of MDMA (more than 250 mg). Overall, samples 
presented to the services as MDMA were unlikely to 
contain any unexpected active component, with 
adulterated MDMA powder or tablets representing less 
than 10 % of all MDMA samples tested. Caffeine was the 
most common adulterant in these samples. Despite the 
high average purity levels of cocaine (73 %), samples 
presented as cocaine were frequently adulterated with 
potentially harmful substances such as levamisole and 
Drug samples tested by drug checking services between January and July 2018
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phenacetin, as well as local anaesthetics such as lidocaine 
and tetracaine. Among all substances tested at drug 
checking services, samples presented as amphetamine 
were the most adulterated, with an average purity of 34 %, 
and often containing high levels of caffeine.
Amphetamines: variation in use but stable trends
Amphetamine and methamphetamine, two closely related 
stimulants, are both consumed in Europe, although 
amphetamine is much more commonly used. 
Methamphetamine consumption has historically been 
restricted to Czechia and, more recently, Slovakia, although 
recent years have seen increases in use in other countries. 
In some datasets, it is not possible to distinguish between 
these two substances; in these cases, the generic term 
amphetamines is used.
Both drugs can be taken orally or nasally; in addition, use 
by injection constitutes a significant part of the drug 
problem in some countries. Methamphetamine can also be 
smoked, but this route of administration is not commonly 
reported in Europe.
It is estimated that 12.4 million adults in the European 
Union (aged 15-64), or 3.7 % of this age group, have tried 
amphetamines during their lives. Figures for recent use 
among young adults (aged 15-34) suggest that 1.3 million 
(1.0 %) used amphetamines during the last year, with the 
most recent national prevalence estimates ranging from 
nought in Portugal to 3.9 % in the Netherlands (Figure 2.9). 
The available data suggest that since the start of the 
century, most European countries have experienced 
a relatively stable situation in amphetamines use. Of the 
countries that have produced new surveys since 2016 and 
reported confidence intervals, none reported higher 
estimates, 8 reported a stable trend and 3 reported lower 
estimates than in the previous comparable survey.
A statistical analysis of trends in last year prevalence of 
use of amphetamines in young adults is only possible in 
a small number of countries. Long-term downward trends 
are observable in Denmark, Spain and the United Kingdom 
(Figure 2.9). The fourth comparable survey from the 
Netherlands suggests an upward trend.
Last year prevalence of amphetamines use among young adults (15-34): selected trends and most recent data
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Analysis of municipal wastewater carried out in 2018 
found that mass loads of amphetamine varied 
considerably across Europe, with the highest levels 
reported in cities in the north and east of Europe 
(Figure 2.10). Amphetamine was found at much lower 
levels in cities in the south of Europe.
Of the 38 cities that have data for 2017 and 2018, 21 
reported an increase, 7 a stable situation and 10 
a decrease. Overall, the data from cities with data from 
2011 to 2018 showed a diverse picture, but with relatively 
stable trends in most cities for amphetamine.
Methamphetamine use, generally low and historically 
concentrated in Czechia and Slovakia, now appears to be 
present also in Cyprus, the east of Germany, Spain and 
northern Europe (Figure 2.11). In 2017 and 2018, of the 40 
cities that have data on methamphetamine in wastewater, 
5 reported an increase, 20 a stable situation and 15 
a decrease.
High-risk amphetamines use: high treatment 
demand
Problems related to long-term, chronic and injecting 
amphetamine use have, historically, been most evident in 
northern European countries. In contrast, 
methamphetamine problems have been most apparent in 
Czechia and Slovakia. A 2015 estimate for Germany 
reported 0.19 % or 102 000 adult high-risk amphetamines 
users. Users of amphetamines are likely to make up the 
majority of the estimated 2 234 (0.18 %) high-risk 
stimulant users reported by Latvia in 2017, down from 
6 540 (0.46 %) in 2010. In Czechia, high-risk 
methamphetamine use among adults (15-64) was 
estimated at around 0.50 % in 2017 (corresponding to 
34 700 users). This represents an increase from 20 900 
users in 2007, though numbers have been relatively stable 
in recent years. The estimate for Cyprus was 0.03 % or 176 
users in 2017.
Approximately 30 000 clients entering specialised drug 
treatment in Europe in 2017 reported amphetamines as 
their primary drug, of whom about 12 000 were first-time 
clients. Primary amphetamine users account for 15 % or 
more of first-time treatment entrants in Germany, Latvia, 
Poland and Finland, and an increasing trend has been 
observed in Germany since 2009. Treatment entrants 
reporting primary methamphetamine use are concentrated 
in Czechia, Slovakia, Poland and Turkey, which together 
Amphetamine residues in wastewater in selected European cities: trends and most recent data
mg/1 000 population/day
NB: Mean daily amounts of amphetamine in milligrams per 1 000 population. Sampling was carried out in selected European cities over a week in each year from 
2011 to 2018.
Source: Sewage Analysis Core Group Europe (SCORE).
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account for 88 % of the 5 000 methamphetamine clients 
entering specialised treatment in Europe. Amphetamines 
are the drugs with the smallest gender gap, though women 
still represent only about one-quarter (26 %) of 
amphetamine clients. Considering route of administration, 
14 % of all entrants reported oral consumption of 
amphetamines, 65 % reported sniffing and 9 % reported 
injecting.
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NB: Apart from the map, data are for all treatment entrants with amphetamines as primary drug. Data for Germany, Sweden and Norway relate to clients citing 
a stimulant other than cocaine as primary drug.
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Ketamine, GHB and hallucinogens: 
use remains low
A number of other substances with hallucinogenic, 
anaesthetic, dissociative or depressant properties are used 
in Europe: these include LSD (lysergic acid diethylamide), 
hallucinogenic mushrooms, ketamine and GHB (gamma-
hydroxybutyrate).
The recreational use of ketamine and GHB (including its 
precursor GBL, gamma-butyrolactone) has been reported 
among subgroups of drug users in Europe for the last two 
decades. National estimates, where they exist, of the 
prevalence of GHB and ketamine use in adult and school 
populations remain low. In their 2017 survey, Norway 
reported last year prevalence of GHB use at 0.1 % for 
adults (16-64). In 2017, last year prevalence of ketamine 
use among young adults (16-34) was estimated at 0.6 % in 
Denmark and 1.7 % in the United Kingdom.
The overall prevalence levels of LSD and hallucinogenic 
mushroom use in Europe have been generally low and 
stable for a number of years. Among young adults (15-34), 
national surveys report last year prevalence estimates of 
less than 1 % for both substances in 2017 or most recent 
survey year, with the exception of Finland (1.9 %) and 
the Netherlands (1.6 %) for hallucinogenic mushrooms, 
and Norway (1.1 %) and Finland (1.3 %) for LSD.
New psychoactive substances: low use 
and decreasing treatment demands
Since 2011, more than half of the European countries have 
reported national estimates of the use of new psychoactive 
substances (not including ketamine and GHB) in their 
general population surveys, although differences in 
methods and survey questions limit comparisons between 
countries. Among young adults (aged 15-34), last year 
prevalence of use of these substances ranged from 0.1 % 
in Norway to 3.2 % in the most recent findings from the 
Netherlands, in 2016, with 4-fluoroamphetamine (4FA) 
being the most commonly used. Survey data on the use of 
mephedrone are available for the United Kingdom 
(England and Wales). In the most recent survey (2017), 
last year use of this drug among 16- to 34-year-olds was 
estimated at 0.2 %, down from 1.1 % in 2014/15. In their 
most recent surveys, last year estimates of the use of 
synthetic cannabinoids among 15- to 34-year-olds ranged 
from 0.1 % in the Netherlands to 1.5 % in Latvia.
While consumption levels of new psychoactive substances 
are low overall in Europe, in a 2016 EMCDDA study over 
two-thirds of countries reported that their use by high-risk 
drug users resulted in health concerns. In particular, the 
use of synthetic cathinones by opioid and stimulant 
injectors has been linked to health and social problems. In 
addition, the smoking of synthetic cannabinoids in 
marginalised populations, including among homeless 
people and prisoners, has been identified as a problem in 
a number of European countries.
Overall, few people currently enter treatment in Europe for 
problems associated with use of new psychoactive 
substances. For some countries, however, these 
substances are significant. In the most recent data, the 
use of synthetic cannabinoids was reported as the main 
reason for entering specialised drug treatment for 19 % of 
clients in Turkey and for 6 % in Hungary. Problems related 
to the primary use of synthetic cathinones were cited by 
0.2 % of treatment entrants in the United Kingdom. All 
three countries, however, have reported a recent decrease 
in treatment entries related to new psychoactive 
substances in the most recent data.
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High-risk opioid use: first-time heroin 
presentations decrease in most countries
In Europe, the most commonly used illicit opioid is heroin, 
which may be smoked, snorted or injected. A range of 
synthetic opioids such as methadone, buprenorphine and 
fentanyl are also misused.
Europe has experienced different waves of heroin 
addiction, the first affecting many western countries from 
the mid-1970s and a second wave affecting other 
countries, especially those in central and eastern Europe, 
in the mid to late 1990s. In recent years, the existence of 
an ageing cohort of high-risk opioid users, who are likely to 
have been in regular or sporadic contact with substitution 
treatment and other services, has been identified.
The prevalence of high-risk opioid use among adults 
(15-64) is estimated at 0.4 % of the EU population, the 
equivalent of 1.3 million high-risk opioid users in 2017. At 
national level, prevalence estimates of high-risk opioid use 
range from less than 1 to more than 8 cases per 1 000 
population aged 15-64. The five most populous countries 
in the European Union, accounting for 62 % of its 
population, contain three-quarters (77 %) of its estimated 
number of high-risk opioid users (Germany, Spain, France, 
Italy, United Kingdom). Of the 12 countries with regular 
estimates of high-risk opioid use between 2008 and 2017, 
Greece, Malta, Slovenia and Spain show a statistically 
significant decrease while Czechia and Ireland (up to 
2014) show a statistically significant increase 
(Figure 2.12).
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In 2017, use of opioids was reported as the main reason 
for entering specialised drug treatment by 171 000 clients 
or 35 % of all those entering drug treatment in Europe. Of 
these, 32 000 were first-time entrants. Primary heroin 
users accounted for 78 % (20 500 clients) of first-time 
primary opioid users entering treatment, a drop of 4 700 
clients or 17 % compared with the previous year.
According to available trend data, the number of first-time 
heroin clients more than halved from a peak in 2007, 
to a low point in 2013 before stabilising in recent years. 
Between 2016 and 2017, the number of first-time 
treatment entrants for primary heroin use decreased in 
16 countries out of the 27 with available data.
Synthetic opioids: diverse substances seen across 
Europe
While heroin remains the most commonly used illicit 
opioid, a number of sources suggest that licit synthetic 
opioids (such as methadone, buprenorphine and fentanyl) 
are increasingly misused. Opioids other than heroin 
reported by treatment entrants include misused 
methadone, buprenorphine, fentanyl, codeine, morphine, 
tramadol and oxycodone. Such opioids now account for 
22 % of all primary opioid clients and in some countries, 
non-heroin opioids represent the most common form of 
opioid use among specialised treatment entrants. In 2017, 
19 European countries reported that more than 10 % of all 
opioid clients entering specialised services presented for 
problems primarily related to opioids other than heroin 
(Figure 2.13). In Estonia, the majority of treatment entrants 
reporting an opioid as their primary drug were using 
fentanyl, while buprenorphine was the most cited primary 
opioid among treatment entrants in Finland. 
Buprenorphine misuse is reported by around 22 % of 
opioid clients in Czechia and the misuse of methadone by 
33 % of opioid clients in Germany and 19 % in Denmark. In 
Cyprus and Poland, between 20 % and 50 % of opioid 
clients enter treatment for problems related to the use of 
other opioids, such as oxycodone (Cyprus) and ‘kompot’ 
— heroin made from poppy straw (Poland). In addition, 
those entering treatment for problems relating to new 
psychoactive substances with opioid-like effects may be 
reported under the general heading of opioids.
HEROIN USERS ENTERING TREATMENT
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Injecting drug use continues to decline among new 
heroin clients
Injecting drug use is most commonly associated with 
opioids, although in a few countries, the injection of 
stimulants such as amphetamines or cocaine is also 
common.
Only 16 countries have estimates of the prevalence of 
injecting drug use since 2012, where they range from less 
than 1 to more than 10 cases per 1 000 population aged 
15-64. In most of these countries, the main injected drug 
can be identified clearly, though in some countries two 
drugs have similar high levels of use. Opioids are reported 
as a main injected drug in the majority (14) of the 
countries (see Figure 2.14). Heroin is mentioned in 12 of 
these countries, while buprenorphine is named in Finland 
and fentanyl in Estonia. Stimulants are reported as a main 
injected drug in 4 countries, where the substances used 
include synthetic cathinones (Hungary), cocaine (France), 
amphetamine (Latvia) and methamphetamine (Czechia).
Treatment entrants citing opioids as primary drug: by type of opioid (left) and percentage reporting opioids other than heroin (right)
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Among first-time clients entering specialised drug 
treatment in 2017 with heroin as their primary drug, 25 % 
reported injecting as their main route of administration, 
down from 43 % in 2006. In this group, levels of injecting 
vary between countries, from 8 % in Spain to 90 % or more 
in Latvia. Injecting is reported as the main route of 
administration by less than 1 % of first-time cocaine clients 
and 9 % of first-time primary amphetamines clients. The 
overall picture for amphetamines, however, is influenced 
by Czechia, which accounts for more than 50 % of new 
amphetamines clients injecting the drug in Europe. 
Considering the three main injected drugs together, among 
first-time entrants to treatment in Europe, injecting as the 
main route of administration has declined from 26 % in 
2006 to 11 % in 2017 (Figure 2.15).
The injection of synthetic cathinones, although not 
a widespread phenomenon, continues to be reported in 
specific populations, including opioid injectors and drug 
treatment clients in some countries and among needle 
exchange clients in Hungary. In a recent EMCDDA study, 
10 countries reported synthetic cathinone injection — 
often with other stimulants and GHB. This is most usually 
reported in the context of sex parties among men who 
have sex with men.
Injecting drug use: most recent estimates of prevalence of injecting any drug in the last year and main drug injected
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Insights from syringe residue data: stimulant drugs 
commonly found
Data from drug treatment and high-risk drug use estimates 
can be complemented by findings from the European 
Syringe Collection and Analysis Project Enterprise 
(ESCAPE) network, which collates information on injected 
substances by analysing the residual content of used 
syringes. The syringes were collected from the bins of 
street automatic injection kit dispensers and at harm-
reduction services in a network of five sentinel EU cities in 
2017: Amsterdam, Budapest, Glasgow, Helsinki and Paris. 
The contents of 1 288 used syringes were tested in five 
laboratories.
The results suggest that the substances injected vary 
between and within cities (Figure 2.16). A high proportion 
of the syringes in all five cities contained stimulants, with 
cocaine, amphetamines and synthetic cathinones often 
found. Half of the syringes tested contained two or more 
drugs; the most frequent combination being a mix of 
stimulant and opioid. Where benzodiazepines were found, 
they were often in syringes with opioids.
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Drug-related harms 
and responses
The use of illicit drugs is a recognised 
contributor to the global burden of 
disease. Chronic and acute health 
problems are associated with the use of 
illicit drugs, and these are compounded 
by various factors including properties 
of the substances, the route of 
administration, individual vulnerability 
and the social context in which drugs 
are consumed. Chronic problems 
include dependence and drug-related 
infectious disease, while there is 
a range of acute harms, with drug 
overdose the best documented of 
these. Although relatively rare, the use 
of opioids still accounts for much of the 
morbidity and mortality associated with 
drug use. Injecting drug use increases 
risks. In comparison, although the 
health problems associated with 
cannabis use are clearly lower, the high 
prevalence of use of this drug may have 
implications for public health. The 
variation in content and purity of 
substances now available to users 
increases potential harms and creates 
a challenging environment for drug-
related responses.
Monitoring drug-related harms and responses
Information on health and social responses to drug 
use, including drug strategies and drug-related 
public expenditure, are provided to the EMCDDA by 
Reitox national focal points and expert working 
groups. Expert ratings provide supplementary 
information on the availability of interventions where 
more formalised datasets are unavailable. This 
chapter is also informed by reviews of the scientific 
evidence on the effectiveness of public health 
interventions. Supporting information can be found 
on the EMCDDA website in the Health and social 
responses to drug problems: a European guide and 
associated online material, and the Best practice 
portal.
Drug-related infectious diseases and mortality and 
morbidity associated with drug use are the principal 
health harms monitored systematically by the 
EMCDDA. These are complemented by more limited 
data on acute drug-related hospital presentations 
and data from the EU Early Warning System, which 
monitors harms associated with new psychoactive 
substances. Further information is available online 
under Key epidemiological indicators, the Statistical 
Bulletin and Action on new drugs.
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The design and delivery of effective evidence-based 
responses to drug problems is a central focus for European 
drug policies and involves a range of measures. Prevention 
and early intervention approaches aim to prevent drug use 
and related problems, while treatment, including both 
psychosocial and pharmacological approaches, represents 
the primary response to dependence. Some core 
interventions, such as opioid substitution treatment and 
needle and syringe programmes, were developed in part as 
a response to injecting opioid use and related problems, 
particularly the spread of infectious diseases and overdose 
deaths. As drug problems change new approaches need to 
be developed and evaluated, some of which are discussed 
below.
Drug strategies: approaches to evaluation
Nearly half of the 30 countries monitored by the EMCDDA 
now have national drug strategies that include different 
combinations of substance-based and behavioural 
addiction issues alongside illicit drugs. These planning 
tools are used by governments to elaborate their overall 
approach and specific responses to the different health, 
social and security dimensions of drug problems. While 
Denmark’s national drug policy is expressed in a range of 
strategic documents, legislation and concrete actions, all 
other countries have a national drug strategy document. In 
14 countries, the policy focus is broader, also giving 
consideration to other addictive substances and 
behaviours (see Figure 3.1). However, within the United 
Kingdom, the devolved administrations of Scotland, Wales 
and Northern Ireland have broad strategy documents. 
When these three documents are included, the total 
number of broad illicit drug strategies increases to 17. 
These documents generally focus on illicit drugs, and there 
is variation in how other substances and addictions are 
considered. All documents address alcohol, 10 consider 
tobacco, 9 cover medicines, 8 also include other addictive 
behaviours, such as gambling. Whatever the focus, all 
national drug strategies explicitly endorse the balanced 
approach to drug policy put forward in the EU drug strategy 
(2013-20) and action plan (2017-20), which emphasises 
the importance of both drug demand reduction and drug 
supply reduction. This extended strategy scope brings with 
it the possibility of achieving a more integrated public 
health approach, but also challenges in terms of 
coordinating implementation, monitoring and evaluation.
Focus of national drug strategy documents (left) and approaches to evaluation (right) in 2018
Multi-criterion evaluation
Implementation 
progress review
Issue specific evaluation
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Illicit drugs focus
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other addictions. While the United Kingdom has an illicit drug strategy, 
Scotland, Wales and Northern Ireland have broad strategy documents which 
include alcohol.
FIGURE 3.1
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All European countries evaluate their national drug 
strategies, though they do so through a range of different 
approaches. Evaluations generally aim to assess the level 
of strategy implementation achieved and changes in the 
overall drug situation over time. In 2018, 13 multi-criteria 
evaluations, 9 implementation progress reviews and 3 
issue-specific evaluations were reported as having recently 
taken place, while 5 countries used other approaches, 
such as a mix of indicator assessments and research 
projects (see Figure 3.1). The trend towards the use of 
broadly focused strategies is gradually being mirrored by 
the use of evaluations with an equally broader focus. 
Currently, France, Luxembourg, Sweden and Norway have 
published evaluations of broadly focused strategies.
Substance use prevention: environmental 
approaches
The prevention of drug use and drug-related problems 
among young people is a key objective in European 
national drug strategies and covers a wide range of 
approaches. Environmental and universal approaches 
target entire populations, selective prevention targets 
vulnerable groups who may be at greater risk of developing 
drug use problems and indicated prevention focuses on at-
risk individuals.
The ‘Icelandic model’ of prevention, which involves the 
consistent application of a combination of effective 
prevention principles at population level, has recently 
received much international attention. The approach 
includes supervised after-school leisure time with 
universal access to sport and cultural activities for youth, 
alongside parental monitoring and curfew hours for 
under-18-year-olds. In Europe, the Icelandic model has 
been implemented in some municipalities in Spain, the 
Netherlands and Romania. Further evaluation will be 
needed to clarify whether the significant decline in 
substance use observed in Iceland during the last decade, 
which mirrors adolescent substance use decline in some 
other European countries, is linked primarily to the 
country’s prevention strategy and its alcohol policy, or 
whether other factors are important.
The Icelandic model is based on an environmental 
prevention approach that posits the idea that it is possible 
to change unwanted behaviour by altering the physical, 
economic and regulatory aspects of the environment that 
provide or reduce opportunities for the behaviour to occur. 
This in turn can lead to a decrease in their acceptability, 
normality and visibility. Measures can include regulating 
the availability and pricing of substances, reducing alcohol 
serving sizes and reducing outlet density.
Environmental prevention principles are also central to the 
Good Behaviour Game, a manual-based programme for 
primary school children, which has been shown in some 
research studies to have beneficial effects. It is intended to 
reduce risk behaviours by using behavioural incentives at 
the group level to reinforce positive norms and rules. At 
a broader level, the changed status and reduction in 
cigarette smoking in many EU countries is arguably an 
example of an environmental prevention approach in 
practice.
Professional training does appear to be important for the 
successful introduction of prevention approaches. A recent 
initiative has seen the launch of a European Universal 
Prevention Curriculum, based on evidence and 
international standards, for regional or local decision and 
opinion-makers. In 2018, the curriculum was being 
implemented at some level in one-third of EU Member 
States.
 All European countries  
 evaluate their national  
 drug strategies 
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Responding to drug use: new technologies
Interventions for drug prevention and treatment are 
constantly evolving, and the use of novel digital solutions 
including the use of computer-based technologies is 
increasing. Digital interventions (‘apps’) may use a range 
of devices, from desktop computers to mobile devices, and 
increasingly smartphones. These mobile or m-health apps 
are used for a wide range of purposes, including drug 
prevention, harm-reduction, digital outreach within social 
media platforms, patient monitoring and supervision, and 
treatment delivery (Figure 3.2). Some apps provide 
practical assistance, including drug glossaries, information 
and advice. An innovative example is the use of geo-
location to help people who inject drugs find needle and 
syringe exchange points. Others are based on effective 
prevention techniques such as social norms approaches, 
and challenging misperceptions around peer drug use. 
Although there are now many m-health apps available to 
the public, a recent EMCDDA study found that few had 
been scientifically evaluated, quality standards were 
lacking and there were concerns around data protection.
The application of virtual reality technology is also being 
investigated as a medium for providing exposure therapy. 
Using virtual reality headsets, realistic and immersive 
drug-related environments are created that induce 
cravings, and patients are trained in techniques to address 
these.
Drug treatment: outpatient services dominate
Drug treatment remains the primary intervention utilised 
for individuals who experience problems with their drug 
use, including dependence. Ensuring good access to 
appropriate treatment services is therefore a key policy 
objective.
The majority of drug treatment in Europe is provided in 
outpatient settings, with specialised treatment centres 
representing the largest provider in terms of number of 
drug users treated (Figure 3.3). Low-threshold agencies 
are the second largest providers followed by primary 
healthcare and general mental healthcare centres. This 
last category includes general practitioners’ surgeries, 
which are important prescribers of opioid substitution 
treatment in some large countries such as France and 
Germany. Elsewhere, for example in Poland and Slovenia, 
outpatient mental healthcare centres play a role in 
treatment provision.
A smaller share of drug treatment in Europe is provided in 
inpatient settings, mainly hospital-based residential 
centres (e.g. psychiatric hospitals), but also therapeutic 
communities and specialised residential treatment 
centres. The relative importance of outpatient and 
inpatient provision within national treatment systems 
varies greatly between countries.
Accessing drug treatment: self-referral is most 
common route
An estimated 1.2 million people received treatment for 
illicit drug use in the European Union during 2017 
(1.5 million including Norway and Turkey). Self-referral 
continues to be the most common route into specialised 
drug treatment. It can include referral by family members 
or friends and accounted for more than half (54 %) of 
those entering specialised drug treatment in Europe in 
2017. About 17 % of clients were referred by the criminal 
justice system, while 15 % were referred by health, 
education and social services, including other drug 
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treatment centres. In a number of countries, schemes are 
in place to divert drug offenders away from the criminal 
justice system and into drug treatment programmes. This 
may involve a court order to attend treatment or 
a suspended sentence conditional on treatment.
In 2017, among countries with more than 100 people 
referred to treatment through the criminal justice system, 
the share of clients entering treatment by this route ranges 
from less than 5 % in Czechia, Greece, the Netherlands 
and Poland to about 70 % in Hungary. Overall, primary 
cannabis users are the most likely to be referred to 
treatment by the criminal justice system while primary 
opioid users are the least likely.
Client pathways through drug treatment are often 
characterised by the use of different services, multiple 
entries and varying lengths of stay. Opioid users represent 
the largest group entering and undergoing specialised 
treatment and consume the greatest share of available 
treatment resources, mainly in the form of substitution 
treatment. Cannabis and cocaine users are the second 
and third largest groups entering treatment services 
(Figure 3.4). The services offered for these clients are often 
more diverse but usually based around some form of 
psychosocial intervention. An insight into treatment 
journeys is provided by results from an analysis of 
specialised treatment data from 10 European countries 
between 2014 and 2017. Of the 300 000 clients reported 
in treatment in these countries, over half had been in 
continuous treatment for more than 1 year, many of whom 
had problems related to the use of opioids, particularly 
heroin. The remainder entered treatment in that year. Of 
these, 16 % entered treatment for the first time in their life, 
while 28 % re-entered treatment, having received 
treatment in an earlier year. These data reflect the 
reoccurring and long-term nature of many drug-related 
disorders.
Trends in percentage of clients entering specialised drug treatment, 
by primary drug
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Opioid substitution treatment: varying coverage 
levels
Substitution treatment, often combined with psychosocial 
interventions, is the most common treatment for opioid 
dependence. The available evidence supports this 
approach, with positive outcomes found in respect to 
treatment retention, illicit opioid use, reported risk 
behaviour, drug-related harms and mortality.
An estimated 654 000 opioid users received substitution 
treatment in the European Union in 2017 (662 000 
including Norway). Following a continuous decline 
between 2010 and 2015, the 2017 EU total represents 
a 4 % increase on the previous year. Between 2015 and 
2017, increases were observed in 17 countries, including 
Sweden (21 %), Romania (21 %) and Italy (16 %), while 
recent declines were reported for 9 countries including 
Lithuania (18 %) and Cyprus (17 %).
A comparison with current estimates of the number of 
high-risk opioid users in Europe would suggest that overall 
about half receive substitution treatment, but there are 
differences in coverage between countries (Figure 3.5) and 
some remain below recommended levels. Overall, 
considering those countries where data from 2007 or 
2008 are available for comparison, there was generally an 
increase in coverage.
Methadone is the most commonly prescribed opioid 
substitution drug, received by almost two-thirds (63 %) of 
substitution clients in Europe. A further 34 % are treated 
with medications based on buprenorphine, which is the 
principal medicine used for substitution treatment in 
8 countries (Figure 3.6). Other substances, such as 
slow-release morphine or diacetylmorphine (heroin), are 
more rarely prescribed, being received by an estimated 3 % 
of substitution clients in Europe. The European 
substitution client cohort is ageing, with the majority of 
clients now being over 40 years old and typically receiving 
treatment for more than 2 years. Alternative treatment 
options for opioid users are available in all European 
countries but less commonly used. In the 11 countries for 
which data are available, between 2 % and 17 % of all 
opioid users in treatment receive interventions not 
involving opioid substitution.
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Proportion of clients receiving different types of prescribed opioid substitution medication in European countries
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Responding to drug problems: 
expenditure and implementation mechanisms
Understanding the costs of drug-related actions is 
important for both policy development and policy 
evaluation. However, the information available on drug-
related public expenditure in Europe, at both local and 
national level, remains sparse and heterogeneous. In the 
past decade, 26 countries have produced estimates of 
drug-related public expenditure. The estimates vary in 
scope and range from 0.01 % to 0.5 % of gross domestic 
product (GDP), with about half of the estimates falling 
between 0.05 % and 0.2 % of GDP.
Between 2006 and 2017, 19 countries produced an 
estimate of spending on demand reduction initiatives as 
a share of overall drug-related expenditure. These vary 
substantially between countries, with estimates ranging 
from 8 % to 80 % (Figure 3.7). Where it is known, 
expenditure on drug treatment accounts for a large share 
of estimated demand reduction expenditure.
Successful programme implementation requires a focus 
on, among other things, costs, standards and training. 
Analysis of the cost-effectiveness of drug treatment 
interventions can help optimise the allocation of financial 
resources. Despite the outpatient and prescription costs 
associated with pharmacotherapy for opioid dependence, 
it results in lower total health costs. This is due to those 
receiving this treatment making less frequent use of 
high-cost services such as emergency and inpatient care.
A recent EMCDDA survey found that at least 80 % of the 
reporting countries published some type of guidelines to 
support the implementation of demand reduction 
practices, and 60 % report the use of quality standards. 
Accreditation systems linking the authorisation of service 
provision under publicly funded schemes to the 
implementation of quality standards are reported by 70 % 
of the countries. In addition, most of the countries report 
the availability of training for professionals (80 %). Less 
commonly reported are registries or inventories of 
evidence-based or best practice programmes but these do 
exist in a quarter of the countries. Positively, compared to 
previous years, there has been a substantial increase in 
the proportion of countries that now report that they have 
published guidelines and standards for interventions and 
have set up some kind of accreditation systems for service 
provision. Overall, it appears that the training opportunities 
for professionals working in the drugs field are increasing, 
although it is widely recognised as an area in which further 
investment would be beneficial.
Drug-related public expenditure: estimated breakdown between 
demand reduction and supply reduction
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Acute drug-related harms: cocaine increases 
and heroin decreases
Hospital emergency data can provide an insight into acute 
drug-related harms and the public health impact of the use 
of drugs in Europe. Drug-related acute toxicity 
presentations to 26 (sentinel) hospitals in 18 European 
countries are monitored by the European Drug 
Emergencies Network (Euro-DEN Plus). In 2017, the 
hospitals recorded 7 267 presentations, most of whom 
were male (76 %). Almost three-quarters of the 
presentations were brought to hospital by ambulance, with 
the majority (78 %) discharged within 12 hours. A small 
minority needed, however, to be admitted to critical care 
(6 %) or to a psychiatric ward (4 %). Among the sample, 
30 in-hospital deaths were recorded, of which 17 involved 
opioids.
Cocaine was the drug most commonly involved in 
presentations in 2017, followed by heroin and cannabis 
(Figure 3.8). Almost a quarter of presentations involved the 
misuse of prescription or over-the-counter drugs (most 
commonly benzodiazepines and opioids), over 10 % were 
related to GHB/GBL, and 4 % involved new psychoactive 
substances.
Differences in the drugs involved in emergency 
presentations between sites appear to reflect variations in 
hospital catchment area and local patterns of use. For 
example, emergencies involving amphetamines were most 
common in the north and east of Europe, whereas 
presentations related to cocaine were predominant in the 
south and west of Europe.
Top 25 drugs recorded in emergency presentations in sentinel hospitals in 2017 (left) and frequencies of cocaine and amphetamines 
presentations (percentage of presentations), aggregated by country (right)
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The overall trend for the 15 centres that have reported 
data for 2014-17 shows a decrease in the number of 
presentations related to heroin and an increase for cocaine 
powder and crack cocaine (Figure 3.9). During the same 
period, there was an overall decrease in presentations 
related to synthetic cathinones and an increase related to 
synthetic cannabinoids.
Only a small number of countries monitor acute drug 
emergencies at the national level. Among these, Czechia, 
Denmark, Lithuania and Slovenia reported a decreasing 
trend in heroin-related emergencies. Between 2013 and 
2017, Denmark reported an increase in intoxications 
related to opioids other than heroin and methadone and 
a doubling in the number of cocaine-related intoxications. 
In Spain, cocaine was involved in almost half of the 
reported drug-related emergencies in 2016, while sentinel 
regional reporting in the Netherlands noted a decline in 
emergencies related to MDMA and the stimulant 
4-fluoroamphetamine (4-FA) at first aid posts between 
2016 and 2017. Almost a third of drug-related ambulance 
call outs in the Netherlands were linked to the use of GHB.
Cocaine and crack: health responses
Interventions are available to treat people who use cocaine 
and crack. In Europe these measures tend to focus on 
psychosocial interventions, including cognitive behavioural 
therapy, motivational interviewing, brief interventions, 
contingency management and symptomatic 
pharmacological treatment. Other treatment options 
currently being explored include the use of stimulant 
medications, like modafinil and lisdexamfetamine, to 
reduce craving and withdrawal symptoms, and a cocaine 
vaccine to reduce the euphoric and rewarding effects of 
cocaine.
Currently, the evidence base for what constitutes effective 
treatment options for cocaine-related problems remains 
relatively weak, and this is an area in which more research 
and development is needed. Correspondingly, there is 
limited availability of specialised programmes that 
specifically target cocaine users in Europe. However, in 
response to increases in the numbers seeking treatment 
for cocaine-related problems, some countries report the 
development of tailored interventions. These include 
programmes combining community reinforcement 
approaches with contingency management (Belgium) and 
adapting opening hours to fit the needs of cocaine clients 
(Luxembourg, Austria).
Harm reduction interventions for cocaine and crack users, 
targeting health risks related to cocaine injection or crack 
smoking and risky sexual behaviours, are also available in 
some countries. These include supervised drug 
consumption rooms in Denmark, Germany, France, 
Luxembourg and the Netherlands, and provision of crack 
cocaine kits (pipes and filters in France and Portugal). 
Drug checking services exist in some EU countries, and 
these are intended to reduce the risks associated with 
high-purity or adulterated cocaine.
Trends in the number of presentations to sentinel hospitals related 
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Joint investigations and risk assessment
In 2017, the risks posed by 9 new psychoactive substances, including 5 fentanyl derivatives (acryloylfentanyl, 
furanylfentanyl, 4-fluoroisobutrylfentanyl, tetrahydrofuranylfentanyl and carfentanil), were formally risk-assessed by 
the Scientific Committee of the EMCDDA. They have since been controlled at international level under the terms of 
the 1961 UN convention. 
Following on from the joint EMCDDA-Europol investigations launched in 2017 on cyclopropylfentanyl and 
methoxyacetylfentanyl, these two fentanyl derivatives — involved in more than 90 deaths — were formally risk-
assessed by the EMCDDA during 2018 (Table 1). Based on the findings of the risk assessment reports, and on the 
initiative of the European Commission, the Council of the EU and the European Parliament decided to subject these 
two substances to control measures throughout Europe. 
Table 1. Key findings from the risk assessments of two fentanyl derivatives carried out in 2018
Common name Cyclopropylfentanyl Methoxyacetylfentanyl
Chemical name N-phenyl-N-[1-(2-phenylethyl)piperidin-
4-yl]cyclopropanecarboxamide
2-methoxy-N-phenyl-N-[1-(2-
phenylethyl)piperidin-4-yl]acetamide
Chemical structure
Formal notification to the EU Early 
Warning System
4 August 2017 9 December 2016
Reports of deaths associated with use 78 13
Number of countries where associated 
deaths occurred
3 4 
Number of seizures by law enforcement 144 48
Number of countries where it has been 
seized (EU, Turkey and Norway)
6 10
Total quantity seized 1.76 kg powder;
772 ml liquid;
329 tablets
180 g powder;
352 ml liquid;
119 tablets
New drugs: high-potency synthetic opioids
New psychoactive substances, including synthetic opioids, 
synthetic cannabinoids and synthetic cathinones, continue 
to be associated with deaths and acute intoxications in 
Europe and, despite a range of new measures introduced 
in this area, continue to represent a challenge to current 
drug policy models.
Although playing a small role in Europe’s drug market, new 
opioids pose a serious threat to individual and public 
health. Of particular concern are fentanyl derivatives, 
which make up the majority of new opioids reported to the 
EMCDDA. These substances can be particularly potent, 
with minute quantities capable of causing life-threatening 
poisoning from rapid and severe respiratory depression. 
Reported overdose cases include people who believed 
they were buying heroin, other illicit drugs or pain 
medicines. In addition to the acute risks of overdose, 
where the use of naloxone may be indicated, fentanyl 
derivatives are also reported to have high abuse liabilities 
and dependence-producing potential.
 New opioids pose  
 a serious threat  
 to individual and  
 public health 
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Chronic drug-related harms: local HIV outbreaks, 
late diagnosis
As well as the risks posed by unprotected sex, people who 
use drugs, particularly those who inject them, are at risk of 
contracting infections such as hepatitis C virus (HCV) and 
the human immunodeficiency virus (HIV) through the 
sharing of drug use material. Correspondingly, the 
prevalence of HIV among people who inject drugs is higher 
than in the general population.
In 2017, an estimated 1 046 new HIV diagnoses 
attributable to injecting drug use were notified in the 
European Union, with 83 % being male, mostly over 35 and 
representing 5 % of all HIV diagnoses for which the route 
of transmission is known. This proportion has remained 
low and stable for the last decade. Notifications of newly 
diagnosed HIV infections among people who inject drugs 
have declined in most European countries between 2008 
and 2017 (Figure 3.10). However, injecting drug use 
remains an important mode of transmission in some 
countries. In 2017, according to the data reported to the 
European Centre for Disease Prevention and Control, 
injecting drug use was linked to 62 % of newly diagnosed 
HIV cases in Lithuania and 33 % in Latvia. Seroprevalence 
studies — based on blood samples — from people who 
inject drugs, conducted in Estonia, Latvia and Poland in 
2016-17, found that more than 10 % of those tested were 
HIV-positive.
Localised HIV outbreaks have been documented among 
marginalised populations of people who inject drugs in 
Dublin (2014-15), Luxembourg (2014-16), Munich 
(2015-16) and Glasgow (2015-18). All four outbreaks have 
been associated with stimulant injecting.
Where the information was available, half of the new HIV 
diagnoses attributed to drug injecting in the European 
Union in 2017 were diagnosed late — that is, when the 
virus had already begun to damage the immune system. 
Late HIV diagnosis is associated with delays in initiation of 
anti-retroviral therapy and increased morbidity and 
mortality. The policy of ‘test-and-treat’ for HIV, whereby 
anti-retroviral therapy is started directly after an HIV 
diagnosis, can result in a reduction of transmission and is 
especially important among groups with higher risk 
behaviours, such as people who inject drugs. Early 
diagnosis and initiation of anti-retroviral therapy offers 
those infected a normal life expectancy.
Newly diagnosed HIV cases related to injecting drug use: overall and selected trends and most recent data
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In 2017, 14 % of newly reported AIDS cases in the 
European Union, where the route of transmission was 
known, were attributed to injecting drug use. These 379 
injection-related notifications represent less than a quarter 
of the number reported a decade ago.
HCV prevalence: variation in national trends
Viral hepatitis, particularly infection caused by the hepatitis 
C virus (HCV), is highly prevalent among injecting drug 
users across Europe. For every 100 people infected with 
HCV, 75 to 80 will develop chronic infection. This has 
important long-term consequences, as chronic HCV 
infection, often worsened by heavy alcohol use, will lead to 
increasing numbers of deaths and cases of severe liver 
disease, including cirrhosis and cancer, among an ageing 
population of high-risk drug users.
The prevalence of antibodies to HCV among people who 
inject drugs, indicating present or past infection, is 
estimated from seroprevalence studies or routine 
diagnostic tests offered in drug services. In 2016-17, HCV 
antibody prevalence in national samples of people who 
inject drugs varied from 15 % to 82 %, with 8 of the 14 
countries with national data reporting rates in excess of 
50 % (Figure 3.11). Among countries with national trend 
data for the period 2011-17, declining HCV prevalence 
among people who inject drugs was reported in 6 
countries, while 3 reported an increase.
Among people who inject drugs, hepatitis B virus (HBV) 
infection is less common than HCV infection, but still 
higher than in the general population, despite the 
availability of an effective vaccine. The presence of the 
HBV surface antigen indicates current infection, which 
may be acute or chronic. In the 7 countries with national 
data for 2016/17, between 1 % and 9 % of people who 
inject drugs were estimated to be currently infected with 
HBV.
Drug injection is a risk factor for other infectious diseases, 
and drug-related clusters of hepatitis A were reported in 
Czechia and Germany in 2016. In the United Kingdom, the 
number of notified group A streptococcus cases 
associated with injecting drug use has increased since 
2013, and wound botulism cases continue to be reported 
in Europe.
HCV antibody prevalence among people who inject drugs: seroprevalence studies (SP) and diagnostic test results (DT) with national and 
subnational coverage, 2016-17
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Infectious disease prevention: varying availability 
of effective measures
A range of measures are recommended to reduce drug-
related infectious diseases among people who inject 
drugs. These include the provision of opioid substitution 
treatment, the distribution of sterile syringes, needles and 
other clean injecting equipment, vaccination, testing and 
treatment for viral hepatitis and HIV as well as health 
promotion interventions focused on reducing injecting and 
sexual risk behaviours.
For those who inject opioids, substitution treatment 
significantly lowers infection risk, with some analyses 
indicating increased protective effects when high 
treatment coverage is also combined with high levels of 
syringe provision. Evidence shows that needle and syringe 
programmes are effective in reducing the transmission of 
HIV among people who inject drugs. Of the 30 countries 
monitored by the EMCDDA, all except Turkey provide clean 
injecting equipment at specialised outlets free of charge. 
Information on the provision of syringes through 
specialised programmes is available from 25 countries, 
which together report the distribution of 53 million 
syringes in the most recent year for which data are 
available (2015/17). This is a major underestimation, as 
several large countries, such as Germany, Italy and the 
United Kingdom, do not report full national data on syringe 
provision. In addition, syringes may be purchased from 
pharmacies in some countries. There appears, however, to 
be large variation in coverage of syringe distribution 
schemes across the 15 countries for which data are 
available to allow a comparison with recent estimates of 
the number of people who inject drugs (Figure 3.12).
Besides sterile syringes and needles, pads to disinfect the 
skin, water to dissolve drugs, and clean mixing containers 
are routinely or often provided by harm reduction services 
in many countries (Figure 3.13), while non-injecting 
paraphernalia such as foil and pipes are less common. HIV 
home testing kits can help people who inject drugs 
diagnose infection early. The kits are available for purchase 
in pharmacies in a growing number of European countries 
and, in some, they are provided by harm reduction 
services.
Coverage of specialised syringe programmes: number of syringes provided per estimated person who injects drugs
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HCV elimination: enhancing access to testing 
and treatment
Europe aims to eliminate viral hepatitis as a public health 
threat in line with the global Agenda 2030 for Sustainable 
Development. Providing people who inject drugs with 
greater access to prevention, testing and treatment for 
HBV and HCV is central to achieving this objective. In 
2018, 17 EU countries and Norway had national hepatitis 
strategies or action plans.
HCV screening is the entry point to hepatitis care and 
effective treatment for those tested, and plays a crucial 
role in preventing transmission. Barriers to testing and 
uptake of treatment exist at the system, service provider 
and client levels, and can include factors such as financial 
constraints, poor knowledge about HCV treatment, and 
stigma and marginalisation of drug users. Innovative 
methods are required to overcome these challenges, and 
community-based drugs agencies represent a key setting 
for reaching people who inject drugs with testing and 
referral to care.
European expert guidelines recommend offering HCV 
treatment without delay to individuals at high risk of 
transmitting the virus — which includes prisoners and 
people actively injecting drugs. New oral treatment 
regimens with direct-acting antiviral agents result in a cure 
within 8 to 12 weeks in 95 % of cases. After reductions in 
the price of these medications, the number of European 
countries now providing unrestricted access to direct-
acting antivirals for all groups of patients and all genotypes 
of the virus, regardless of the stage of the infection, is 
increasing.
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Interventions in prisons: national availability differs
Prisoners report higher lifetime rates of drug use and more 
harmful patterns of use, including injecting, than the 
general population, making prisons an important setting 
for drug-related interventions. A recent EMCDDA review 
identified new psychoactive substance use in prisons in 
22 countries (Figure 3.14), with synthetic cannabinoids 
identified as posing the main challenge. New psychoactive 
substances were linked to a wide range of physical and 
mental health harms, whether through acute intoxication 
or chronic consumption. In Latvia, the use of new synthetic 
opioids in prison has been linked to increases in 
overdoses, as well as injecting and needle-sharing.
Infectious diseases testing (HIV, HBV, HCV and 
tuberculosis) is available in prisons in most countries, 
although this may be limited to testing on entry or of 
symptomatic individuals only. The provision of hepatitis 
C treatment is reported in 24 countries, but only in 5 is the 
treatment received by more than 60 % of those in need of 
it. Hepatitis B vaccination programmes are reported to 
exist in 16 countries. The provision of clean injecting 
equipment is less common, with the implementation of 
syringe programmes in this setting reported by 3 countries. 
An analysis of HIV and HCV prevalence among people who 
inject drugs from 17 European countries, covering 2006 to 
2017, found significantly higher HIV and HCV rates among 
individuals with a history of incarceration.
Coverage of treatment interventions offered to prisoners 
varies considerably by country but can include 
detoxification, individual and group counselling, treatment 
in therapeutic communities and in special inpatient wards. 
Some European countries have established interagency 
partnerships between prison health services and providers 
in the community, in order to facilitate delivery of health 
education and treatment interventions in prison and to 
ensure continuity of care upon prison entry and release. 
Preparation for prison release, including social 
reintegration, is reported by all countries. Programmes to 
prevent the risk of drug overdose, which is particularly high 
among opioid injectors in the period after leaving prison, 
are reported in 5 countries, with prisoners trained to 
recognise and respond to overdose, and receiving 
naloxone on release.
In 2017, 28 countries reported allowing the provision of 
opioid substitution treatment in prisons; however, the 
coverage is often low. Opioid substitution treatment can be 
initiated within prison in 24 countries, and in 5 countries it 
can only be continued if treatment started in the 
community.
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Overdose: a main cause of death for high-risk drug 
users
Drug use is a recognised cause of avoidable mortality 
among European adults. Overall, in Europe, people who 
use opioids are between 5 and 10 times more likely to die 
than their peers of the same age and gender. The 
importance of reducing the mortality related to overdose 
among those who use opioids is widely recognised. 
However, other causes of death indirectly related to drug 
use, such as infections, accidents, violence including 
homicide and suicide, are also important causes of 
mortality in this group. Chronic pulmonary and liver 
conditions as well as cardio-vascular problems are 
frequent and now account for an increased share of 
deaths among older and chronic drug users.
Overdose data, especially the European cumulative total, 
must be interpreted with caution. Among the reasons for 
this are systematic under-reporting in some countries, 
differences in the ways toxicological examinations are 
conducted and registration processes that can result in 
reporting delays. Annual estimates therefore represent 
a provisional minimum value.
It is estimated that at least 8 238 overdose deaths, 
involving one or more illicit drug, occurred in the European 
Union in 2017. This rises to an estimated 9 461 deaths if 
Norway and Turkey are included, representing a stable 
situation in relation to the revised estimated figure of 
9 397 in 2016. The overall EU total is also stable compared 
with 2016. As in previous years, the United Kingdom 
(34 %) and Germany (13 %) together account for almost 
half of all reported overdose deaths in the EU, Norway and 
Turkey. This figure needs to be interpreted in the context of 
both the size of the at-risk populations in these countries 
and under-reporting in some other countries. 
Over three-quarters of those dying from overdose are male 
(78 %). The mean age at death continued to increase, 
reaching 39.4 years of age in 2017, with males 2 years 
younger than females. This reflects the ageing nature of 
Europe’s opioid-using population who are at greatest risk 
of drug overdose death. In some countries, a proportion of 
opioid cases may relate to deaths involving opioids in the 
context of long-term pain management.
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Between 2012 and 2017, overdose deaths in the European 
Union increased in all age categories above 30 years 
(Figure 3.15). Deaths among the 50+ age groups increased 
by 62 % overall, while deaths among younger age groups 
have generally been stable. Analysis of fatal overdoses 
reported by Turkey in 2017 shows a younger profile than 
the European Union average, with a mean age of 32 years 
(Figure 3.16).
Drug-induced mortality: above-average rates 
reported in northern Europe
The mortality rate due to overdoses in Europe in 2017 is 
estimated at 22.6 deaths per million population aged 
15-64. The rate among males (35.8 cases per million 
males) is almost four times that among females (9.3 cases 
per million females). National mortality rates and trends 
vary considerably (Figure 3.17) and are influenced by 
factors such as prevalence and patterns of drug use, 
particularly injecting opioid use; risk and protective factors, 
such as the availability of treatment; as well as by national 
practices of reporting, recording information and coding 
overdose cases, including variable levels of under-
reporting, in national mortality databases. According to the 
latest data available, rates of over 40 deaths per million 
population were reported in 8 northern European 
countries, with the highest rates reported in Estonia 
(130 per million) and Sweden (92 per million) 
(Figure 3.17).
Number of drug-induced deaths reported in the European Union in 
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Fatal overdoses: most deaths involve opioids
Opioids, mainly heroin or its metabolites, often in 
combination with other substances, are present in the 
majority of fatal overdoses reported in Europe. The most 
recent data show an increase in the number of opioid-
related deaths in some European countries, for example in 
the United Kingdom, where 9 out of 10 overdose deaths 
(89 %) involved some form of opioid.
In France, heroin was implicated in 26 % of overdose 
deaths in 2016, compared with 15 % in 2012, whereas 
methadone was present in more than a third (36 %) of the 
deaths. Other opioids are also regularly found in 
toxicological reports. These substances, primarily 
methadone, but also buprenorphine (Finland), fentanyl and 
its derivatives (particularly in Estonia) and tramadol, are 
associated with a substantial share of overdose deaths in 
some countries. The increase in overdose deaths reported 
in Czechia in 2017 was mainly due to an increase in cases 
related to fentanyl-like substances, morphine and codeine; 
the increase reported in Slovakia mostly involved tramadol.
Stimulants such as cocaine, amphetamines, MDMA and 
cathinones are implicated in a smaller number of overdose 
deaths in Europe, although their significance varies by 
country. In France, a fifth of the deaths involved cocaine, 
and half of these also involved opioids. In Slovenia, where 
most of the deaths involved heroin, cocaine was found in 
around a third of cases. In 2017, Turkey reported 185 
MDMA-related deaths, a decline compared with 2016.
Turkey also reported a large increase in the number of 
deaths related to synthetic cannabinoids: from 137 in 
2015 to 563 in 2017. Synthetic cannabinoids were present 
in 60 % of all drug-related deaths reported in the country, 
and most of the cases were young males in their twenties. 
In more than a quarter of these cases, cannabis was also 
found. In the United Kingdom, in particular for Scotland, an 
increase in the number of deaths involving new 
psychoactive substances linked with benzodiazepines has 
been reported.
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Preventing overdoses and drug-related deaths: 
key approaches
Reducing overdose morbidity and mortality is a major 
public health challenge in Europe. A broader public health 
response in this area aims at reducing vulnerability among 
those who use drugs, especially by removing barriers and 
making services accessible, and by empowering drug 
users to take fewer risks (Figure 3.18). Assessing overdose 
risk among people who use drugs and strengthening their 
overdose awareness, combined with providing effective 
drug treatment, helps to prevent the occurrence of 
overdoses. Periods of known elevated risk, such as release 
from prison and discharge or drop-out from treatment, 
require particular attention. Interventions such as 
supervised drug consumption facilities as well as ‘take-
home’ naloxone programmes are targeted responses, 
which aim at improving the likelihood of surviving an 
overdose. The importance of opioid substitution treatment 
in reducing mortality is evident in a 2018 meta-analysis of 
studies in this area.
Supervised drug consumption facilities are spaces where 
drug users can consume drugs in hygienic and safer 
conditions. This intervention aims both to prevent 
overdoses from occurring and to ensure that professional 
support is available if an overdose occurs. They also 
provide an opportunity to engage with often marginalised 
and hard-to-reach populations of users and deliver 
drug-related and general health advice and support. 
Typically, consumption rooms also provide a point of 
access and referral to other medical and social services, 
including drug treatment services. It has also been argued 
that by reducing drug use in public, they contribute to 
improving the social environment in areas where this 
occurs, for example urban drug markets.
Individual facilities may supervise a large number of 
consumptions — with 80 000 consumptions per year 
reported by some of the bigger facilities — that would 
otherwise would have taken place in the streets or in other 
risky settings. The first generation of drug consumption 
facilities in the 1980s and 1990s focused mainly on 
supervising injecting heroin use. Today, however, facilities 
may also supervise people who snort, smoke or inhale 
drugs. In the European Union and Norway, supervised 
consumption facilities operate in 51 cities, with a total of 
72 facilities in operation.
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Reversing opioid overdose: take-home naloxone
Naloxone is an opioid antagonist medication used in 
hospital emergency departments and by ambulance 
personnel to reverse opioid overdose. In recent years, there 
has been an expansion of take-home naloxone 
programmes, which provide overdose training and make 
the medication available to those likely to witness an 
opioid overdose.
Recent systematic reviews of the effectiveness of take-
home naloxone programmes have found evidence that its 
provision in combination with educational and training 
interventions reduces overdose-related mortality.
In 2018, community-based take-home naloxone 
programmes were operating in 10 European countries. 
These programmes are commonly run by drugs and health 
services, with the exception of Italy, where naloxone is an 
over-the-counter medication. Prisoners are included as a 
target population in the take-home naloxone programmes 
in Estonia, France, the United Kingdom and Norway.
 Reducing overdose morbidity  
 and mortality is a major  
 public health challenge 
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Annex
 National data for estimates of drug use prevalence including  
 problem opioid use, substitution treatment, total number in  
 treatment, treatment entry, injecting drug use, drug-induced  
 deaths, drug-related infectious diseases, syringe distribution  
 and seizures. The data are drawn from and are a subset  
 of the EMCDDA Statistical Bulletin 2019, where notes  
 and meta-data are available. The years to which data refer  
 are indicated. 
Annex: National data tables
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TABLE A1 
OPIOIDS
High-risk opioid 
use estimate
Entrants into treatment during the year
Clients in 
substitution 
treatment
Opioids clients as % of treatment entrants % opioids clients injecting (main route of administration)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country Year of estimate
cases per 
1 000 % (count) % (count) % (count) % (count) % (count) % (count) count
Belgium – – 22.5 (2 493) 8.2 (345) 32 (2 048) 14.1 (309) 9 (28) 15.2 (272) 16 546
Bulgaria – – 67.8 (1 136) 55.9 (100) 89.7 (600) 64.4 (437) 53.8 (50) 66.7 (377) 3 247
Czechia 2017 1.8-2.0 19.1 (799) 10.9 (192) 25.6 (565) 63.9 (470) 57.4 (101) 66.1 (347) 5 000
Denmark – – 12 (587) 7.5 (170) 16.5 (399) 17.5 (94) 5.6 (9) 22 (80) 7 050
Germany (1) 2016-17 0.9-3.0 29.9 (–) 9.6 (–) – 20.1 (–) 17.9 (–) – 78 800
Estonia – – 93.4 (271) 87.4 (76) 95.5 (150) 69.3 (187) 72 (54) 80.7 (121) 1 186
Ireland 2014 6.1-7.0 44.9 (3 837) 24.8 (807) 58.8 (2 860) 31.7 (1 180) 23 (184) 33.6 (930) 10 316
Greece 2017 1.8-2.5 60.9 (2 593) 38.9 (652) 74.8 (1 892) 28.7 (733) 22.2 (143) 31 (581) 9 388
Spain 2016 1.5-2.9 26.8 (12 235) 13.3 (3 043) 42.6 (8 573) 14.9 (1 796) 7 (212) 17.2 (1 454) 58 749
France 2017 4.5-5.9 27.3 (12 899) 13.7 (1 813) 44 (8 039) 16.4 (1 842) 10.4 (174) 19.3 (1 360) 178 665
Croatia 2015 2.5-4.0 – 21.2 (203) – – 30.9 (56) – 4 792
Italy 2017 5.7-6.4 43.1 (20 095) 28.3 (5 921) 55.3 (14 174) 40.9 (7 137) 28.4 (1 395) 45.8 (5 742) 69 642
Cyprus 2017 1.6-2.6 25.2 (212) 13.8 (58) 41.8 (137) 50.5 (104) 40.4 (23) 56 (75) 209
Latvia 2017 4.7-7.0 49.4 (399) 28.7 (123) 72.8 (276) 82.8 (323) 73.8 (90) 86.9 (233) 669
Lithuania 2016 2.7-6.5 85.3 (1 448) 57 (138) 91.1 (1 298) 85.5 (1 236) 86.9 (119) 85.4 (1 108) 1 136
Luxembourg 2015 4.5 60.9 (109) 60.4 (29) 59.5 (47) 41.7 (43) 50 (14) 41.9 (18) 1 142
Hungary 2010-11 0.4-0.5 4 (192) 1.8 (61) 9.4 (104) 40.5 (66) 36.2 (21) 43.9 (43) 669
Malta 2017 4.2-4.9 69.7 (1 274) 32.8 (76) 75.1 (1 198) 55.2 (690) 21.1 (16) 57.5 (674) 1 025
Netherlands 2012 1.1-1.5 11.5 (1 262) 6.2 (402) 19.3 (860) 6.1 (39) 7.6 (13) 5.6 (26) 5 241
Austria 2017 6.1-6.5 48.7 (1 793) 27.8 (432) 63.8 (1 361) 37.7 (529) 21.8 (70) 42.5 (459) 18 632
Poland 2014 0.4-0.7 15.8 (1 122) 5.9 (211) 26.2 (898) 57.4 (636) 37.4 (79) 62.2 (550) 2 685
Portugal 2015 3.8-7.6 41.4 (1 247) 23 (376) 63.3 (871) 13.1 (155) 9.3 (33) 14.7 (122) 16 888
Romania 2017 0.8-2.9 25.7 (918) 14.1 (359) 56.9 (551) 84.7 (729) 83.3 (295) 85.8 (429) 1 530
Slovenia 2017 3.2-4.2 86.5 (211) 67.7 (42) 93.4 (169) 44.1 (93) 21.4 (9) 49.7 (84) 3 042
Slovakia – – 26.3 (760) 12 (154) 39.5 (601) 70.7 (525) 53.6 (81) 75.2 (442) 620
Finland 2012 3.8-4.5 51.1 (363) 36.5 (92) 59.2 (271) 76 (275) 66.3 (61) 79.3 (214) 3 329
Sweden (2) – – 24.2 (9 387) 15.5 (2 140) 29 (7 247) – – – 4 468
United 
Kingdom (3)
2014-15 8.3-8.7 49.8 (57 430) 21.8 (8 051) 63.1 (49 252) 31.8 (12 407) 16.5 (746) 33.9 (11 633) 149 420
Turkey 2011 0.2-0.5 58.6 (6 817) 43.4 (2 451) 72.9 (4 366) 27.3 (1 858) 17.8 (437) 32.5 (1 421) –
Norway (4) 2013 2.0-4.2 17 (973) 11.2 (302) 22.1 (672) – – – 7 622
European Union – – 35.1 (163 557) 16.6 (28 845) 47.9 (129 944) 29.1 (38 450) 20.8 (4 988) 31.3 (32 839) 654 086
EU, Turkey and 
Norway
– – 35.4 (171 347) 17.4 (31 598) 48.2 (134 982) 29.0 (40 308) 20.5 (5 425) 31.4 (34 260) 661 708
Data on entrants into treatment are for 2017 or most recent year available: Estonia and Spain, 2016; Netherlands, 2015.
Data on clients in substitution treatment are for 2017 or most recent year available: Spain and Slovenia, 2016; Denmark, Hungary, Netherlands and Finland, 2015. 
The number for Sweden does not represent all clients.
(1) Due to changes in treatment entry reporting system, only proportions are presented.
(2) Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative of the national 
picture.
(3) The high-risk opioid use estimate does not include Northern Ireland. Clients in substitution treatment relates to England and Wales.
(4) The percentage of clients in treatment for opioid-related problems is a minimum value, not accounting for opioid clients registered as polydrug users.
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TABLE A2
COCAINE
Prevalence estimates Entrants into treatment during the year
General population School population
Cocaine clients as % of treatment 
entrants
% cocaine clients injecting 
(main route of administration)
Year of 
survey
Lifetime, 
adults 
(15-64) 
Last 12 
months, 
young adults 
(15-34)
Lifetime, 
students 
(15-16)
All entrants First-time entrants
Previously 
treated 
entrants
All clients First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium 2013 – 0.9 1 24.3 (2 690) 23.9 (1 007) 24.2 (1 552) 6.2 (124) 1.4 (11) 8.6 (97)
Bulgaria 2016 0.9 0.5 2 2.7 (46) 3.9 (7) 1.6 (11) 0 (0) 0 (0) 0 (0)
Czechia 2017 2.4 0.2 1 0.7 (28) 0.7 (12) 0.7 (15) 0 (0) 0 (0) 0 (0)
Denmark 2017 6.4 3.9 2 15.9 (776) 17.9 (407) 14 (338) 2.1 (15) 0.3 (1) 4.1 (13)
Germany (1) 2015 3.8 1.2 3 4.8 (–) 6.4 (–) – 1.5 (–) 0.8 (–) –
Estonia 2008 – 1.3 1 0.3 (1) 1.1 (1) – – – –
Ireland 2015 7.8 2.9 3 16.8 (1 431) 23 (748) 12.8 (623) 1.3 (18) 0 (0) 2.6 (16)
Greece 2015 1.3 0.6 1 8.1 (345) 10.3 (172) 6.8 (172) 9.9 (34) 4.7 (8) 15.2 (26)
Spain 2017 10.3 2.8 3 39.2 (17 889) 39.7 (9 052) 38.2 (7 678) 0.8 (134) 0.4 (33) 1.3 (98)
France 2017 5.6 3.2 4 8.4 (3 988) 7.8 (1 035) 9.8 (1 801) 8.8 (324) 3.8 (37) 13.6 (229)
Croatia 2015 2.7 1.6 2 – 3.2 (31) – – 3.2 (1) –
Italy 2017 6.9 1.7 2 33 (15 394) 38.1 (7 993) 28.9 (7 401) 2 (299) 1.1 (86) 3 (213)
Cyprus 2016 1.4 0.4 3 14.7 (124) 12.1 (51) 19.8 (65) 5 (6) 2 (1) 7.9 (5)
Latvia 2015 1.5 1.2 2 0.5 (4) 0.7 (3) 0.3 (1) 0 (0) 0 (0) 0 (0)
Lithuania 2016 0.7 0.3 2 0.8 (13) 2.1 (5) 0.5 (7) 11.1 (1) 33.3 (1) 0 (0)
Luxembourg 2014 2.5 0.6 2 21.8 (39) 14.6 (7) 25.3 (20) 40.5 (15) 57.1 (4) 42.1 (8)
Hungary 2015 1.2 0.9 2 3.5 (167) 3.9 (132) 2.4 (26) 2.5 (4) 2.3 (3) 4 (1)
Malta 2013 0.5 – 3 18.6 (340) 41.8 (97) 15.2 (243) 13.4 (43) 4.1 (4) 17.5 (39)
Netherlands 2017 6.2 4.5 2 24.3 (2 675) 20.8 (1 357) 29.6 (1 318) 0.4 (5) 0.1 (1) 0.6 (4)
Austria 2015 3.0 0.4 2 9.2 (339) 10.1 (156) 8.6 (183) 9.3 (30) 5.4 (8) 12.6 (22)
Poland 2014 1.3 0.4 4 2.3 (163) 2.5 (88) 2.1 (72) 2.5 (4) 1.2 (1) 2.9 (2)
Portugal 2016 1.2 0.3 2 17.3 (522) 20.8 (341) 13.2 (181) 2.6 (13) 0.6 (2) 6.3 (11)
Romania 2016 0.7 0.2 3 1.2 (44) 1.4 (36) 0.6 (6) 0 (0) 0 (0) 0 (0)
Slovenia 2012 2.1 1.2 2 4.5 (11) 6.5 (4) 3.9 (7) 45.5 (5) 25 (1) 57.1 (4)
Slovakia 2015 0.7 0.3 2 1.1 (31) 1.9 (24) 0.3 (5) 3.3 (1) – 25 (1)
Finland 2014 1.9 1.0 1 0.1 (1) 0 (0) 0.2 (1) 0 (0) 0 (0) 0 (0)
Sweden (2) 2017 – 2.5 1 1.4 (552) 2.7 (371) 0.7 (181) – – –
United 
Kingdom
2017 10.7 4.7 3 17.6 (20 290) 22.1 (8 185) 15.4 (12 054) 1.9 (259) 0.5 (31) 2.9 (226)
Turkey 2017 0.2 0.1 – 3.9 (456) 4.4 (247) 3.5 (209) 0 (0) 0 (0) 0 (0)
Norway 2017 5.1 2.1 1 1.8 (102) 2.7 (72) 1 (30) – – –
European 
Union
– 5.4 2.1 – 15.5 (72 424) 19.1 (33 178) 16.5 (36 594) 2.1 (1 550) 0.8 (259) 3.1 (1 241)
EU, Turkey 
and Norway
– – – – 15.1 (72 982) 18.4 (33 497) 15.9 (36 833) 2.1 (1 550) 0.8 (259) 3.1 (1 241)
Prevalence estimates for the school population are extracted from ESPAD Survey 2015, except for Belgium (2017; Flanders only), Bulgaria (2017), Germany 
(2011), Italy (2017), Luxembourg (2014, age 15 years), Spain (2016), Sweden (2017) and United Kingdom (2016; England only, age 15 years). Due to uncertainty 
of data collection procedures, Latvia data may not be comparable.
United Kingdom general population prevalence estimates refer to England and Wales only. Age range for general population prevalence rates: France, Germany, 
Greece and Hungary, 18-64, 18-34; Denmark and Norway, 16-64, 16-34; Malta, 18-65; Sweden, 17-34; United Kingdom, 16-59, 16-34.
Data on entrants into treatment are for 2017 or most recent year available: Estonia and Spain, 2016; Netherlands, 2015.
(1) Due to changes in treatment entry reporting system, only proportions are presented.
(2) Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative of the national 
picture.
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TABLE A3
AMPHETAMINES
Prevalence estimates Entrants into treatment during the year
General population School population
Amphetamines clients as % of treatment 
entrants
% amphetamines clients injecting 
(main route of administration)
Year of 
survey
Lifetime, 
adults 
(15-64)
Last 12 
months, 
young adults 
(15-34)
Lifetime, 
students 
(15-16)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium 2013 – 0.5 1 9.1 (1 011) 7.5 (315) 10.6 (681) 11.8 (96) 6.2 (16) 14.6 (80)
Bulgaria 2016 1.5 1.8 3 12.6 (211) 12.8 (23) 2.7 (18) 4.9 (2) 0 (0) 11.8 (2)
Czechia 2017 3.3 0.7 1 49.6 (2 078) 52.8 (933) 47.2 (1 041) 62.8 (1 256) 57.6 (520) 67.2 (683)
Denmark 2017 7.0 1.4 1 6.2 (303) 5.4 (122) 7 (170) 1.8 (5) 0.9 (1) 2.5 (4)
Germany (1) 2015 3.6 1.9 4 14.5 (–) 15.3 (–) – 2.1 (–) 1.9 (–) –
Estonia 2008 – 2.5 2 3.8 (11) 6.9 (6) 2.5 (4) 50 (5) 66.7 (4) 33.3 (1)
Ireland 2015 4.1 0.6 3 0.4 (38) 0.6 (19) 0.3 (17) – – –
Greece – – – 2 0.8 (33) 1.3 (22) 0.4 (11) 18.2 (6) 22.7 (5) 9.1 (1)
Spain 2017 4 0.9 2 1.7 (754) 1.9 (431) 1.4 (291) 0.9 (7) 0.9 (4) 1 (3)
France 2017 2.2 0.6 2 0.4 (212) 0.5 (63) 0.5 (91) 9.7 (18) 8.5 (5) 10.8 (9)
Croatia 2015 3.5 2.3 3 – 3.4 (33) – – 0 (0) –
Italy 2017 2.4 0.3 2 0.2 (93) 0.3 (55) 0.1 (38) 1.2 (1) 2 (1) 0 (0)
Cyprus 2016 0.5 0.1 3 6.8 (57) 6.2 (26) 9.5 (31) 9.1 (5) 4 (1) 13.3 (4)
Latvia 2015 1.9 0.7 3 17.5 (141) 22.9 (98) 11.3 (43) 64.1 (84) 54.9 (50) 85 (34)
Lithuania 2016 1.2 0.5 1 3.5 (59) 9.9 (24) 2 (29) 29.6 (16) 13.6 (3) 48.1 (13)
Luxembourg 2014 1.6 0.1 1 – – – – – –
Hungary 2015 1.7 1.4 3 11.1 (534) 11.2 (378) 11.3 (124) 9.7 (51) 4.8 (18) 27 (33)
Malta 2013 0.3 – 2 0.2 (3) 0.4 (1) 0.1 (2) 66.7 (2) 100 (1) 50 (1)
Netherlands 2017 5.4 3.9 2 7.4 (817) 7.5 (487) 7.4 (330) 1.3 (4) 1 (2) 1.9 (2)
Austria 2015 2.2 0.9 3 5.5 (203) 7.2 (111) 4.3 (92) 2.2 (4) 1 (1) 3.6 (3)
Poland 2014 1.7 0.4 4 29.4 (2 085) 31.6 (1 126) 26.9 (924) 2.7 (55) 1.3 (15) 4.3 (39)
Portugal 2016 0.4 0.0 1 0.1 (3) 0.1 (2) 0.1 (1) 0 (0) 0 (0) 0 (0)
Romania 2016 0.3 0.1 1 0.8 (30) 1 (26) 0.4 (4) 0 (0) 0 (0) 0 (0)
Slovenia 2012 0.9 0.8 1 0.8 (2) 3.2 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Slovakia 2015 1.4 0.8 1 40.8 (1 182) 44 (566) 38.1 (580) 30.9 (350) 26.8 (148) 34.9 (192)
Finland 2014 3.4 2.4 1 18.9 (134) 20.2 (51) 18.1 (83) 71.2 (94) 52 (26) 82.9 (68)
Sweden (2) 2017 – 1.2 1 5.3 (2 076) 7.3 (1 007) 4.3 (1 069) – – –
United 
Kingdom
2017 9.9 1.0 1 2.1 (2 476) 2.7 (1 015) 1.9 (1 450) 18.9 (295) 11.7 (70) 23.6 (225)
Turkey 2017 0.0 – – 6.5 (751) 9.7 (549) 3.4 (202) 0 (0) 0 (0) 0 (0)
Norway 2017 3.9 0.8 1 13 (744) 10.3 (277) 15.4 (467) – – –
European 
Union
– 3.7 1.0 – 6.1 (28 291) 6.6 (11 393) 5.9 (16 465) 9.4 (2 871) 8.8 (1 015) 9.3 (1 714)
EU, Turkey 
and Norway
– – – – 6.2 (29 786) 6.7 (12 219) 6.0 (17 134) 9.2 (2 871) 8.4 (1 015) 9.2 (1 714)
Prevalence estimates for the school population are extracted from ESPAD Survey 2015, except for Belgium (2017; Flanders only), Bulgaria (2017), Germany 
(2011), Italy (2017), Luxembourg (2014, age 15 years), Spain (2016), Sweden (2017) and United Kingdom (2016; England only, age 15 years). Due to uncertainty 
of data collection procedures, Latvia data may not be comparable.
United Kingdom general population prevalence estimates refer to England and Wales only. Age range for general population prevalence rates: France, Germany and 
Hungary, 18-64, 18-34; Denmark and Norway, 16-64, 16-34; Malta, 18-65; Sweden, 17-34; United Kingdom, 16-59, 16-34.
Data on entrants into treatment are for 2017 or most recent year available: Estonia and Spain, 2016; Netherlands, 2015. Data for Germany, Sweden and Norway 
refer to users of ‘stimulants other than cocaine’.
(1) Due to changes in treatment entry reporting system, only proportions are presented.
(2) Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative of the national 
picture.
90
European Drug Report 2019: Trends and Developments
TABLE A4
MDMA
Prevalence estimates Entrants into treatment during the year
General population School population MDMA clients as % of treatment entrants
Year of 
survey
Lifetime, 
adults 
(15-64)
Last 12 
months, 
young 
adults 
(15-34)
Lifetime, 
students 
(15-16)
All entrants First-time entrants
Previously 
treated entrants
Country % % % % (count) % (count) % (count)
Belgium 2013 – 0.8 2 0.5 (53) 0.8 (32) 0.3 (19)
Bulgaria 2016 2.1 3.1 2 1.7 (29) 1.1 (2) 0 (0)
Czechia 2017 5.8 2.1 3 0.6 (27) 1 (17) 0.4 (9)
Denmark 2017 3.2 1.5 1 0.3 (16) 0.6 (14) 0.1 (2)
Germany 2015 3.3 1.3 2 – – –
Estonia 2008 – 2.3 3 0.3 (1) – 0.6 (1)
Ireland 2015 9.2 4.4 4 0.5 (42) 0.9 (29) 0.3 (13)
Greece 2015 0.6 0.4 1 0.2 (10) 0.4 (7) 0.1 (3)
Spain 2017 3.6 1.2 2 0.2 (89) 0.3 (66) 0.1 (16)
France 2017 3.9 1.3 2 0.4 (168) 0.4 (54) 0.3 (56)
Croatia 2015 3.0 1.4 2 – 0.8 (8) –
Italy 2017 2.7 0.8 1 0.1 (59) 0.2 (34) 0.1 (25)
Cyprus 2016 1.1 0.3 3 0.1 (1) – –
Latvia 2015 2.4 0.8 3 0.4 (3) 0.2 (1) 0.5 (2)
Lithuania 2016 1.7 1.0 2 0.1 (2) 0 (0) 0.1 (2)
Luxembourg 2014 1.9 0.4 1 0.6 (1) 2.1 (1) –
Hungary 2015 4.0 2.1 2 2.3 (111) 1.7 (57) 3.7 (41)
Malta 2013 0.7 – 2 0.7 (12) 0.9 (2) 0.6 (10)
Netherlands 2017 9.4 7.1 3 0.7 (80) 1 (67) 0.3 (13)
Austria 2015 2.9 1.1 2 0.9 (32) 1.2 (19) 0.6 (13)
Poland 2014 1.6 0.9 3 0.3 (23) 0.3 (12) 0.3 (9)
Portugal 2016 0.7 0.2 2 0.2 (7) 0.2 (3) 0.3 (4)
Romania 2016 0.5 0.2 2 0.9 (33) 1.2 (30) 0.2 (2)
Slovenia 2012 2.1 0.8 2 0 (0) 0 (0) 0 (0)
Slovakia 2015 3.1 1.2 3 0.1 (4) 0.1 (1) 0.1 (2)
Finland 2014 3.0 2.5 1 0.1 (1) 0.4 (1) 0 (0)
Sweden 2017 – 2.0 1 – – –
United Kingdom 2017 10.0 3.3 4 0.5 (616) 1.1 (415) 0.3 (200)
Turkey 2017 0.4 0.2 – 2 (230) 2.9 (161) 1.2 (69)
Norway 2017 4.1 2.2 1 – – –
European Union – 4.1 1.7 – 0.3 (1 428) 0.5 (872) 0.2 (442)
EU, Turkey and Norway – – – – 0.3 (1 658) 0.6 (1 033) 0.2 (511)
Prevalence estimates for the school population are extracted from ESPAD Survey 2015, except for Belgium (2017; Flanders only), Bulgaria (2017), Germany 
(2011), Italy (2017), Luxembourg (2014, age 15 years), Spain (2016), Sweden (2017) and United Kingdom (2016; England only, age 15 years). Due to uncertainty 
of data collection procedures, Latvia data may not be comparable.
United Kingdom general population prevalence estimates refer to England and Wales only. Age range for general population prevalence rates: France, Germany, 
Greece and Hungary, 18-64, 18-34; Denmark and Norway, 16-64, 16-34; Malta, 18-65; Sweden, 17-34; United Kingdom, 16-59, 16-34.
Data on entrants into treatment are for 2017 or most recent year available: Estonia and Spain, 2016; Netherlands, 2015.
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TABLE A5
CANNABIS
Prevalence estimates Entrants into treatment during the year
General population School population Cannabis clients as % of treatment entrants
Year of 
survey
Lifetime, 
adults 
(15-64)
Last 12 
months, 
young 
adults 
(15-34)
Lifetime, 
students 
(15-16)
All entrants First-time entrants
Previously 
treated entrants
Country % % % % (count) % (count) % (count)
Belgium 2013 15.0 10.1 18 34.2 (3 786) 50.7 (2 132) 23.2 (1 487)
Bulgaria 2016 8.3 10.3 20 9.9 (166) 5 (9) 2.5 (17)
Czechia 2017 28.6 19.3 37 23.6 (988) 28.4 (501) 19.6 (433)
Denmark 2017 38.4 15.4 12 62.7 (3 069) 65.9 (1 501) 59.5 (1 435)
Germany (1) 2015 27.2 13.3 19 43.1 (–) 64.1 (–) –
Estonia 2008 – 13.6 25 1 (3) 2.3 (2) 0.6 (1)
Ireland 2015 27.9 13.8 19 24.6 (2 102) 39 (1 270) 14.6 (712)
Greece 2015 11.0 4.5 9 26.9 (1 148) 46.1 (773) 14.7 (373)
Spain 2017 35.2 18.3 31 29.2 (13 304) 40.7 (9 278) 15.9 (3 208)
France 2017 44.8 21.8 31 59.6 (28 205) 74.4 (9 828) 41.1 (7 517)
Croatia 2015 19.4 16.0 21 – 62.9 (602) –
Italy 2017 32.7 20.9 19 21.8 (10 155) 30.9 (6 483) 14.3 (3 672)
Cyprus 2016 12.1 4.3 7 52.7 (444) 67.5 (284) 28.4 (93)
Latvia 2015 9.8 10.0 17 24 (194) 36 (154) 10.6 (40)
Lithuania 2016 10.8 6.0 18 6.5 (110) 22.7 (55) 3.5 (50)
Luxembourg 2014 23.3 9.8 20 16.2 (29) 22.9 (11) 13.9 (11)
Hungary 2015 7.4 3.5 13 63 (3 031) 68.2 (2 310) 49.2 (542)
Malta 2013 4.3 – 13 9.1 (167) 19 (44) 7.7 (123)
Netherlands 2017 26.6 17.5 22 47.3 (5 202) 55.5 (3 625) 35.4 (1 577)
Austria 2015 23.6 14.1 20 33.2 (1 222) 51.7 (802) 19.7 (420)
Poland 2014 16.2 9.8 24 31.2 (2 209) 39 (1 390) 23.2 (796)
Portugal 2016 11.0 8.0 15 37.2 (1 120) 51.8 (848) 19.8 (272)
Romania 2016 5.8 5.8 8 49.3 (1 764) 62.4 (1 585) 15.8 (153)
Slovenia 2012 15.8 10.3 25 6.1 (15) 19.4 (12) 1.7 (3)
Slovakia 2015 15.8 9.3 26 25.7 (743) 38.5 (495) 14.3 (218)
Finland 2014 21.7 13.5 8 18 (128) 31.3 (79) 10.7 (49)
Sweden (2) 2017 – 9.6 6 10 (3 878) 15.4 (2 125) 7 (1 753)
United Kingdom 2017 30 12.3 19 24.2 (27 920) 45.3 (16 733) 14.2 (11 114)
Turkey 2017 2.7 1.9 – 6.4 (745) 9.2 (520) 3.8 (225)
Norway 2017 24.5 10.1 7 28.8 (1 651) 36.8 (989) 21.8 (662)
European Union – 27.4 14.4 – 32.7 (152 373) 47.0 (81 566) 17.5 (58 103)
EU, Turkey and Norway – – – – 32.0 (154 769) 45.7 (83 075) 17.2 (58 990)
Prevalence estimates for the school population are extracted from ESPAD Survey 2015, except for Belgium (2017; Flanders only), Bulgaria (2017), Germany 
(2011), Italy (2017), Luxembourg (2014, age 15 years), Spain (2016), Sweden (2017) and United Kingdom (2016; England only, age 15 years). Due to uncertainty 
of data collection procedures, Latvia data may not be comparable.
United Kingdom general population prevalence estimates refer to England and Wales only. Age range for general population prevalence rates: France, Germany, 
Greece and Hungary, 18-64, 18-34; Denmark and Norway, 16-64, 16-34; Malta, 18-65; Sweden, 17-34; United Kingdom, 16-59, 16-34.
Data on entrants into treatment are for 2017 or most recent year available: Estonia and Spain, 2016; Netherlands, 2015.
(1) Due to changes in treatment entry reporting system, only proportions are presented.
(2) Data for clients entering treatment refer to hospital-based care and specialised outpatient care facilities. Data shown are not fully representative of the national 
picture.
92
European Drug Report 2019: Trends and Developments
TABLE A6
OTHER INDICATORS
Country
Drug-induced deaths HIV diagnoses 
related to 
injecting drug 
use 
(ECDC)
Injecting drug use estimate
Syringes 
distributed 
through 
specialised 
programmes
Year
All ages Aged 15-64
count
cases per 
million 
population 
(count)
cases per 
million 
population 
(count)
year of 
estimate
cases per 
1 000 
population
count
Belgium 2014 61 8 (60) 0.6 (7) 2015 2.32-4.61 1 203 077
Bulgaria 2017 18 4 (18) 4.4 (31) – – 52 927
Czechia 2017 42 5 (35) 0.5 (5) 2017 6.18-6.47 6 409 862
Denmark (1) 2016 237 55 (202) 1 (6) – – –
Germany (1) (2) 2017 1 272 21 (1 120) 1.5 (127) – – –
Estonia 2017 110 130 (110) 10.6 (14) 2015 9.01-11.25 1 997 158
Ireland 2015 224 69 (215) 2.9 (14) – – 519 578
Greece 2017 62 – (–) 8 (86) 2017 0.43-0.68 278 415
Spain (3) 2016 483 16 (482) 2.3 (105) 2016 0.25-0.57 1 503 111
France (4) 2015 373 7 (299) 0.6 (43) 2017 2.58-3.29 11 907 416
Croatia 2017 65 23 (64) 0 (0) 2015 1.79-2.87 244 299
Italy 2017 294 8 (293) 1.6 (94) – – –
Cyprus 2017 16 26 (15) 0 (0) 2017 0.38-0.59 245
Latvia 2017 22 17 (22) 40 (78) 2016 5.31-6.83 833 817
Lithuania 2017 83 44 (83) 47.8 (136) 2016 4.37-4.89 251 370
Luxembourg 2017 8 19 (8) 15.2 (9) 2015 3.77 447 681
Hungary 2017 33 5 (33) 0.1 (1) 2015 0.98 137 580
Malta 2017 5 16 (5) 0 (0) – – 315 541
Netherlands 2017 262 22 (243) 0.1 (2) 2015 0.07-0.09 –
Austria 2017 154 26 (151) 1.4 (12) – – 6 293 593
Poland (1) 2016 204 7 (181) 0.7 (27) – – 59 958
Portugal 2016 30 4 (30) 1.7 (18) 2015 1.00-4.46 1 421 666
Romania (5) 2017 32 2 (32) 4.4 (86) – – 1 095 284
Slovenia 2017 47 32 (44) 0 (0) – – 578 926
Slovakia 2017 19 5 (18) 0 (0) – – 395 877
Finland 2017 200 55 (189) 1.8 (10) 2012 4.1-6.7 5 824 467
Sweden 2017 626 92 (574) 2 (20) – – 517 381
United Kingdom (6) 2016 3 256 74 (3 108) 1.7 (115) 2004-11 2.87-3.22 –
Turkey (1) 2017 941 17 (907) 0.2 (14) – – –
Norway 2016 282 75 (258) 1.3 (7) 2016 2.15-3.04 2 884 230
European Union – 8 238 23 (7 634) 2.0 (1 046) – – –
EU, Turkey and 
Norway
– 9 461 22.6 (8 799) 1.8 (1 067) – – –
(1) In some cases, the age band is not specified and these cases were not included in the calculations of mortality rate: Germany (147), Denmark (5), Poland (1), 
Turkey (22).
(2) HIV data for Germany refer to 2016.
(3) Syringes distributed through specialised programmes refer to 2016.
(4) Syringes distributed through specialised programmes refer to 2015.
(5) Drug-induced deaths: sub-national coverage.
(6) Syringe data: England, no data; Scotland 4 401 387 and Wales 2 630 382 (both in 2017): Northern Ireland 310 005 (2016).
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TABLE A7
SEIZURES
Heroin Cocaine Amphetamines MDMA, MDA, MDEA
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number 
of 
seizures
Country kg count kg count kg count tablets (kg) count
Belgium 53 1 790 44 752 4 695 163 2 855 491 183 (–) 1 692
Bulgaria 698 32 42 30 406 80 2 335 (322) 41
Czechia 19 90 27 227 95 1 703 15 279 (5) 387
Denmark 16 561 151 4 786 322 2 244 2 731 476 (34) 933
Germany 298 – 8 166 – 1 784 – 693 668 (–) –
Estonia <0.1 3 17 154 33 454 – (6) 310
Ireland – 765 – 792 – 91 – (–) 344
Greece 359 1 952 234 596 164 16 589 (6) 83
Spain 524 7 283 40 960 42 206 272 4 505 363 138 (–) 3 569
France 658 4 544 17 500 12 214 405 773 1 130 839 (–) 1 073
Croatia 27 140 466 418 38 775 – (9) 743
Italy 610 2 296 4 084 7 812 72 271 10 844 (8) 267
Cyprus 0.4 4 8 118 1 73 159 (3) 13
Latvia 0.2 66 2 61 21 502 3 660 (28) 169
Lithuania 4 173 623 98 28 278 – (22) 140
Luxembourg 1 69 3 222 0.2 26 956 (<0.1) 25
Hungary 21 34 6 276 25 973 51 836 (1) 650
Malta 13 25 0.3 232 <0.1 1 405 (<0.1) 99
Netherlands (1) 1 110 – 14 629 – 146 – – (1 250) –
Austria 70 967 71 1 571 55 1 488 446 465 (4) 1 183
Poland 2 2 69 9 608 33 – (–) –
Portugal 29 492 2 734 816 1 51 1 598 (2) 282
Romania 4 222 8 169 2 115 18 810 (0.9) 477
Slovenia 11 286 12 277 6 242 1 537 (1) 63
Slovakia 0.6 41 3 42 4 661 2 448 (<0.1) 74
Finland 0.4 138 7 383 259 2 263 66 420 (–) 695
Sweden 45 675 162 3 640 770 5 524 34 919 (24) 1 993
United Kingdom 844 11 075 5 697 18 912 1 356 4 043 513 259 (2) 3 483
Turkey 17 385 12 932 1 476 3 829 7 268 9 405 8 606 765 (–) 6 663
Norway 99 628 80 1 185 503 5 734 33 657 (12) 1 122
European Union 5 418 36 786 140 435 104 348 7 037 43 720 6 581 823 (1 727) 22 803
EU, Turkey and Norway 22 902 50 346 141 990 109 362 14 808 58 859 15 222 245 (1 739) 30 588
Amphetamines includes amphetamine and methamphetamine.
All data are for 2017 or most recent year.
(1) Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures. Cocaine seizures 
represent the majority of large seizures.
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TABLE A7
SEIZURES (continued)
Cannabis resin Herbal cannabis Cannabis plants
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number 
of seizures
Country kg count kg count plants (kg) count
Belgium 947 6 133 946 28 519 416 576 (–) 1 234
Bulgaria 0.2 9 1 580 57 16 087 (33 822) 102
Czechia 9 173 1 095 5 369 54 392 (–) 502
Denmark 6 637 16 678 293 1 803 38 859 (236) 380
Germany 1 295 – 7 731 – 101 598 (–) –
Estonia 80 54 54 823 – (24) 35
Ireland – 257 – 1 546 – (–) 280
Greece 6 251 257 24 940 8 866 46 907 (–) 742
Spain 334 919 157 346 34 517 151 968 1 124 674 (–) 3 038
France 67 300 82 797 20 200 44 301 137 074 (–) 395
Croatia 8 351 2 410 7 057 7 405 (–) 213
Italy 18 755 8 922 90 097 11 253 265 635 (–) 1 545
Cyprus 1 8 151 826 161 (–) 23
Latvia 202 36 43 848 – (102) 55
Lithuania 2 089 53 124 924 – (–) –
Luxembourg 19 348 113 935 74 (–) 13
Hungary 114 153 3 674 3 751 5 287 (–) 156
Malta 591 109 0.2 175 11 (–) 5
Netherlands (1) 942 – 3 104 – 722 618 (–) –
Austria 100 1 841 1 557 16 969 31 102 (–) 533
Poland 1 237 18 1 043 93 448 (–) 8
Portugal 14 790 3 647 410 437 22 910 (–) 158
Romania 6 185 276 2 861 6 780 (1 540) 179
Slovenia 20 126 838 3 768 13 594 (–) 218
Slovakia 1 26 144 1 115 2 299 (–) 31
Finland 693 252 322 1 158 15 200 (–) 1 150
Sweden 2 809 13 140 1 125 8 825 – (–) –
United Kingdom 6 281 12 093 12 615 103 695 340 531 (–) 9 583
Turkey 81 429 8 718 94 379 41 929 – (–) 3 143
Norway 2 035 9 533 385 3 473 – (43) 167
European Union 466 097 311 071 209 401 440 295 3 370 222 (35 725) 22 745
EU, Turkey and Norway 549 561 329 322 304 165 485 697 3 370 222 (35 768) 26 055
All data are for 2017 or most recent year.
(1) Data on number and quantity of seizures do not include all relevant law enforcement units and should be considered partial, minimum figures.
Getting in touch with the EU
In person
All over the European Union there are hundreds of Europe Direct 
information centres. You can find the address of the centre nearest you at: 
https://europa.eu/european-union/contact_en
On the phone or by email
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service:
– by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for 
these calls),
– at the following standard number: +32 22999696 or
– by email via: https://europa.eu/european-union/contact_en
Finding information about the EU
Online
Information about the European Union in all the official languages of the 
EU is available on the Europa website at: https://europa.eu/european-
union/index_en
EU publications
You can download or order free and priced EU publications at: https://
publications.europa.eu/en/publications. Multiple copies of free 
publications may be obtained by contacting Europe Direct or your local 
information centre (see https://europa.eu/european-union/contact_en).
EU law and related documents
For access to legal information from the EU, including all EU law since 
1952 in all the official language versions, go to EUR-Lex at: http://eur-lex.
europa.eu
Open data from the EU
The EU Open Data Portal (http://data.europa.eu/euodp/en) provides 
access to datasets from the EU. Data can be downloaded and reused for 
free, both for commercial and non-commercial purposes.
About this report
The Trends and Developments report presents a top-
level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with the 
online Statistical Bulletin and 30 Country Drug Reports, 
it makes up the 2019 European Drug Report package.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
